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1.1 Cancer and gene knockdown strategies 
Cancer is a genetic disease in which mutational and/or epigenetic changes in the genome 
lead to deregulation of cell growth or cell death mechanisms. Several technologies have 
been used in an attempt to interfere in this aberrant gene expression. For example, antisense 
oligonucleotides and ribozymes have been used for more than a decade to target specific 
RNAs for degradation. Although these methods worked adequately in some simple 
experimental models, they have generally not delivered effective gene silencing in complex 
mammalian systems.  
  Nevertheless, after antisense technologies and ribozymes, in the late 1990s a novel 
mechanism for gene targeting was discovered, RNA interference (RNAi). It soon became 
clear that RNAi represents a particularly efficient a d at least -in vitro- easy to use method 
for the knockdown of the expression of a selective arget gene. Therefore, RNAi is now      
a well-established method for high throughput analysis as well as for functional studies in 
vitro, including mammalian cells. Many pathological conditions rely on the aberrant 
expression of the endogenous normal or mutant genes cau ing, e.g., variation in signal 
transduction pathways, cellular proliferation, apoptosis, or resistance toward external 
factors. Moreover, the infection of an organism can lead to the introduction and the 
expression of foreign genes. While the inhibition of the activity of gene products, e.g., 
through small molecule inhibitors or inhibitory antibodies is one major focus in therapy, 
much attention has now shifted to an earlier step, i. ., the initial knockdown of the specific 







1.2 Biology of colon cancer 
Colorectal cancer (CRC) is one of the most common causes of cancer related deaths all 
over the world (Jemal et al., 2006), with an estimaed incidence of 1 million new cases and 
a mortality of more than 500,000 death annually (Parkin et al., 2005). Colorectal cancer 
could be of sporadic origin with several intrinsic factors (e.g. age, obesity, and 
inflammatory bowel disease) and extrinsic factors (e.g. cigarette smoking, inadequate 
intake of fiber, high consumption of alcohol, and high fat diet) being associated with 
increased risks of colorectal cancer (Giovannucci and Michaud, 2007; Johnson and Lund, 
2007; Tsoi et al., 2009; Terzic et al., 2010; Wei et al., 2010). Familial inheritance plays 
also an important role, where more than one fifth o patients with colorectal cancer have a 
familial history. However, the diagnosis of familial syndromes, such as Lynch syndrome 
and familial adenomatous polyposis, can only be confirmed in 6% of these patients 
(Jasperson et al., 2010). 
Colorectal cancer is a stepwise progression from benign adenoma to malignant 
adenocarcinoma and distant metastasis, giving an early di gnosis as preferred option to 
ease the disease burden (Lieberman, 2010). It occurs in caecum, ascending, transverse, 
descending and sigmoid colon and rectum. Most colorectal cancers, at least two-thirds, are 
adenocarcinomas, arising from the columnar surface epithelium, and few are signet-ring 
cell carcinoma, squamous carcinoma, undifferentiated carcinoma and medullary-type 
adenocarcinoma (solid carcinoma with minimal or no glandular differentiation and slight 
cellular pleomorphism) (Ponz de Leon and Di Gregorio, 2001).  
Many molecular abnormalities have been reported in colorectal carcinoma and it is now 
believed that accumulated alterations of suppressor genes and proto-oncogenes are required 
for the development of colorectal cancers (Vogelstein et al., 1988; Fearon and Vogelstein, 
1990). It has been estimated that a minimum of eight to ten mutational events must 
accumulate during multistep carcinogenesis to produce an invasive colorectal cancer 
(Hamilton SR, 1998) and allowing it to escape growth and regulatory control mechanisms 





pathways, e.g. Wnt signaling pathway, TGF-β signaling and JNK/SAPK pathway (Parveen 
et al., 2010). It was illustrated that colorectal cn er arises through at least two major 
genetic pathways, chromosomal instability and microsatellite instability (Fukushima and 
Takenoshita, 2001).  
Chromosomal instability refers to numerical and structure chromosomal alterations, namely 
gain and/or loss of whole chromosomes or chromosomal segments at a higher rate in          
a population of cells, such as cancer cells, compared with normal cells (Lengauer et al., 
1998). This pathway, accounting for about 85% of CRCs, is characterized by allelic 
imbalance, chromosomal amplification and translocati n. One of the key steps in this 
pathway is mutation of the genes, 3p21 (β-catenin gene), 5q21 (APC gene), 9p (p16 and 
p15 genes), 13q (retinoblastoma gene), 17p (p53 gene), 17q (BRCA1 gene), 18q (DCC and 
SMAD4 genes), and less frequently 16q (E-cadherin gene) (Kinzler et al., 1991). 
Loss or mutation of APC leads to an accumulation of unphosphorylated β-catenin in the 
cytoplasm, translocation of β-catenin to the nucleus and subsequent activation of APC- β -
catenin-T-cell factor (Tcf)/Lef. This stimulates transcription of target genes known to be 
involved in tumorigenesis (e.g. c-myc, cyclin D1, and c-jun) (Rubinfeld et al., 1993; Su et 
al., 1993; Sparks et al., 1998). Germline mutations of the APC gene cause familial 
adenomatous polyposis, an autosomal dominant disorder characterized by the development 
of hundreds to thousands of colorectal adenoma appearing in adolescence or early 
adulthood. APC mutation or allelic losses of 5q are observed in 40-80% of sporadic CRCs 
and are found at a similar frequency in adenomas. Furthermore, mutated APC has been 
detected in the earliest adenoma, suggesting that the mutation is an initiating event for 
sporadic colorectal tumorigenesis (Powell et al., 1992). 
Microsatellite instability (MSI) is the hallmark of hereditary nonpolyposis colorectal cancer 







1.2.1 Mitogen Activated Protein Kinase (MAPK) 
The mitogen activated protein kinase (MAPKs) signaling system plays an essential role in 
the transduction of extracellular signals to cytoplasmic and nuclear effectors that regulate 
various cellular processes (Chen et al., 2001; Johnson and Lapadat, 2002; Pouyssegur et al., 
2002).  
The MAPK cascade is highly conserved system that is involved in various cellular 
functions, including cell proliferation, differentia on and migration. At least four members 
of the MAPK family have been identified, extracellular signal regulated kinase1/2 
(ERK1/2), c-jun-amino-terminal kinase (JNK), p38 and ERK5 (Sturgill and Wu, 1991; 
Nishida and Gotoh, 1993; Nishimoto and Nishida, 2006).  
ERK5, also known as big MAP kinase1 (BMK1), is twice the size of other MAPKs (Lee et 
al., 1995; Zhou et al., 1995). The MAPK pathways are located downstream of many 
growth-factor receptors, including that for epidermal growth factor. Overexpression and 
activation of this receptor are commonly detected in colorectal cancer, and several lines of 
evidence indicate that overexpression and activation of MAPK play an important part in 
progression of the colorectal cancer (Fang and Richardson, 2005). 
ERK5-mediated role proliferation activity may by due to activation of serum and 
glucocorticoid-induced kinase (SGK), a protein kinase that is closely related to the G1/S 
transition of the cell cycle (Buse et al., 1999). The deregulation of the Cyclin D1 gene, a 
key cell proliferation checkpoint, is frequently associated with tumor formation and has 
been shown to be regulated by ERK5 cascade (Mulloy et al., 2003).  
ERK5 is essential for cardiovascular development whereas ERK5 deficient mice show 
cardiovascular abnormalities and angiogenic defects (Regan et al., 2002; Sohn et al., 2002; 





In a previous study conducted in Xenopus laevis, the essential role of ERK5 in neuronal 
differentiation was shown (Nishimoto et al., 2005). 
ERK5 has a unique transcriptional activation activity, where it translocates into the nucleus 
where the unique C-terminal region plays the most important role in this process (Kasler et 
al., 2000; Yan et al., 2001; Akaike et al., 2004). 
1.2.2 C-Myc 
Some reports have indicated that c-Myc can play a very important role in gastric 
carcinogenesis, where the c-myc proto-oncogene is one of the most frequently activated 
oncogenes, and is estimated to be involved in 20% of all human cancers (Dang, 1999; 
Nesbit et al., 1999). The proto-oncogene c-myc encodes a transcription factor c-Myc, which 
has an important role in controlling cell growth, differentiation, apoptosis and viability. 
Mutations or translocations in the coding sequence of c-myc occur in a number of cancers 
such as Burkitt’s lymphoma (Rabbitts et al., 1983; Rabbitts et al., 1984). C-myc is a 
member of the myc gene family which includes N-myc, s-myc, L-myc and B-myc. 
However, only the c-Myc, L-myc and N-myc have neoplastic activity (Marcu et al., 1992; 
Lemaitre et al., 1996; Facchini and Penn, 1998). 
C-myc is expressed in almost all proliferating normal cells where its expression is strictly 
dependent on mitogenic stimuli, and is downregulated in many kinds of cells when they 
induced to de-nucleation or terminal differentiation, special type of apoptosis, (Evan and 
Littlewood, 1993). 
It was reported that overexpression of c-Myc is associated with the presence of metastasis 
and it was also found that c-Myc mRNA was higher in metastatic than in primary lesions 






The proto-oncogene c-myc plays a role in both positive and negative growth via having an 
influence on proliferation, differentiation and apopt sis. Alterations in the level of myc 
expression or protein structure are associated withmany malignancies in humans and 
animals (Askew et al., 1991; Evan and Littlewood, 1993). 
Deregulated expression of c-myc causes cellular immortalization, but is not sufficient to 
induce transformation of primary cells; however, Myc and Ras have been shown to 
cooperate in both transformation and tumorgenesis in vivo (Henriksson and Luscher, 1996; 
Ryan and Birnie, 1997). 
It was found that one third of breast and colon carcinomas have an elevated level of c-Myc 
gene expression (Erisman et al., 1985; Escot et al., 1986). 
C-Myc and other substrates like sap1a and RSK, ERK1/2 substrates, can be phosphorylated 
by ERK5 (English et al., 1998; Kamakura et al., 1999; Moriguchi et al., 1999).  
It was found that there is a relationship between c-My  deregulation and gastric cancer, 
where c-Myc is overexpressed in over 40% of gastric cancer (Milne et al., 2007). C-Myc 
protein was overexpressed in all cases of both intesti al and diffuse type gastric 
adenocarcinoma samples of individuals from Northern Brazil (Calcagno et al., 2006).  
1.3 Basic mechanism and induction of RNAi 
RNAi was first described in plants as an immune respon e to viral infection. As early as 
1928, it was noticed that tobacco plants, which were infected with tobacco ring spot virus, 
grew without any problems.  
The upper leaves showed resistance to the effect of the virus (Wingard, 1928). It is now 
known that dsRNA intermediates produced during virus infection activate the RNAi 
machinery to silence the expression of complementary genes, thus producing immunity to 





several physiologic pathways that are induced by naturally occurring dsRNA in a wide 
variety of eukaryotic organisms including fungi, plants and animals. With some variations, 
these responses are all mediated by a common RNAi pathway that involves processing of 
the dsRNA into short duplexes of about 22 base pairs with characteristic end structure. The 
RNAi machinery can also be induced by experimentally synthetic dsRNA, providing a 
valuable tool for in vivo gene silencing. 
RNA interference (RNAi) was first characterized in the nematode worm Caenorhabditis 
elegans by Fire and colleagues (Fire et al., 1998) who found that double stranded RNA 
(dsRNA) induced a more potent sequence-specific silencing response than single stranded 
antisense RNA alone. Further investigation into this phenomenon demonstrated that 
injection of dsRNA into the gut of the worm caused a systemic silencing of the target gene 
that was passed on to the next generation offspring. 
From that point forward, the emphasis has been not o ly on understanding how this 
phenomenon occurs, but also how it can be exploited as a research tool (Kamath and 
Ahringer, 2003). Through these investigations, RNAi has been shown to greatly facilitate 
both ‘‘reverse genetic’’ experiments (identifying the function of a known gene) and 
‘‘forward genetics’’ experiments (identifying the gene responsible for a given phenotype).  
Classic reverse genetic experiments involve designing siRNAs (chemically or 
enzymatically synthesized) or shRNA-expression constructs targeting a gene of interest. 
Following transient transfection of siRNAs or shRNA encoding plasmids or selection of 
shRNA-expression stable transfectants, the phenotype of the cells is assessed using an 
appropriate functional assay. It is critical in this type of experiments to use adequate 
controls to ensure that the observed phenotype is only due to targeting the gene of interest.  
The discovery of dsRNA- induced gene silencing in C. elegans allowed genetic screens to 
be performed that led to the identification of genes r quired for RNAi in the nematode 
(Tabara et al., 1999). Double stranded-RNA molecules, whether introduced experimentally 





transgenic transcripts, are recognized and cleaved into 21-23 nucleotide siRNA by the 
RNase III like enzyme termed Dicer (Bernstein et al., 2001). 
Different species contain different numbers of Dicer homologous and/or associated proteins 
containing dsRNA binding domains that function to recognize dsRNAs from different 
sources. For example, in Drosophila, Dicer-1 processes miRNA precursors and Dicer-2 
processes long dsRNAs (Lee et al., 2004). In Arabidopsis thaliana, there are four Dicer 
homologous that function together with associated proteins to cleave dsRNA of different 
types. To date, only one Dicer gene has been identified n mammals, and interacting 
proteins regulating Dicer function remain to be identified. Double stranded-RNA cleavage 
by Dicer generates siRNA that contain a 2-nucleotide 3́ overhang  and a 5ʹ-phosphorylated 
terminus both of which are required for activity (Zamore et al., 2000; Bernstein et al., 
2001; Elbashir et al., 2001c; Hutvagner and Zamore, 2002). Processing by Drosophila 
Dicer is adenosine triphosphate (ATP) -dependent and requires a functional RNA helicase 
domain (Nykanen et al., 2001). In contrast, it appears that human dicer may not require 
ATP (Provost et al., 2002; Zhang et al., 2002).  
Introduction of 21 bp siRNA has allowed for the successful application of RNAi 
technology to mammalian systems. However, assays using this method are transient in 
nature and the suppressed phenotype can be lost within several doubling times, most likely 
due to the dilution of the siRNA. While this approach is reliable for short-term studies of 
gene expression, it cannot replace knockout mouse models or allow for precise loss-of-
function genetic screens. 
The first step in the RNAi pathway involves the processing of large dsRNA into small, 21-
23 nucleotide dsRNA molecules (Zamore et al., 2000; Elbashir et al., 2001b). Initial studies 
in Drosophila showed that an RNase III enzyme was responsible for this processing and 
that the siRNA possessed 3ʹ hydroxyl and 5́ phosphate groups and, importantly, a 3ʹ 





    A proposed model for the Dicer involves the ATP-dependent translocation of the enzyme 
along its dsRNA target. The efficiency with which Dicer cleaves a particular dsRNA 
molecule has also been shown to be directly proportional to the length of the target, since 
the longer the dsRNA, the greater is the amount of siRNA produced and hence the more 
potent is the silencing effect (Bernstein et al., 2001). Human Dicer-mediated cleavage of 
dsRNA is though to occur sequentially, beginning at the termini of the dsRNA, and the 
excision of small dsRNA fragments of a defined length (Ketting et al., 2001; Zhang et al., 
2002). 
Following the cleavage of dsRNA into siRNA by Dicer the second important stage of 
mRNA degradation occurs. This is mediated by a protein complex with nuclease activity 
known as RISC which is guided to its target mRNA by the siRNA into the RISC 
(Hammond et al., 2000). This guide role of siRNA was proposed after the observation that 
dsRNA would only lead to the degradation of an mRNA with a homologous sequence, 
leaving the rest of the RNA in the cell unaffected.  
Moreover, it was shown that both siRNA and RISC were required to mediate cleavage of 
the target (Hammond et al., 2000). Following the initial discovery of the existence of a 
ribonucleoprotein complex as a mediator of RNAi, the components and mechanism of 
action of RISC began to be elucidated, and both inactive and active forms of RISC complex 
(the active indicated as  RISC*) were found. It was shown that a second ATP-dependent 
step was involved in the pathway and showed the following unwinding of the siRNA 
duplex (Nykanen et al., 2001). In another seminal study, RISC* was found to be associated 
only with the antisense strand of the siRNA (Martinez et al., 2002). Hence, although the 
siRNA needs to be double stranded in order to be efficiently recognized and bound to 
RISC, the two siRNA strands must unwind before RISC becomes active. The efficient 
cleavage of the target mRNA by RISC was also shown to be dependent on the 







Figure 1.1 RNAi Pathway: Long dsRNA is processed by Dicer into siRNAs which then 
incorporates into RISC, The duplex siRNA is unwound leaving the anti-sense strand to 
guide RISC to complementary mRNA for subsequent endonucleolytic cleavage (Aigner, 
2006). 
In non-mammalian cells, there is evidence that an alternative branch of the RNAi pathway 
which results in the amplification of the original message, can account for the efficiency of 
gene silencing (Sijen et al., 2001). In this case, th  unwound siRNA no longer acts as a 
guide to bring RISC to the target mRNA but simply functions as a primer for an RNA-
dependent RNA polymerase (RdRP), which uses the targ t mRNA as a template to produce  
new dsRNA. This can be subsequently recognized and cleaved by Dicer, thus re-entering 
the RNAi pathway and initiating a new round of silencing. Therfore, not only is the mRNA 
targeted via the specific oligonucleotid sequence (and hence gene expression silenced) but 
also new dsRNAs arising from the entire mRNA sequence are created and thus amplify the 





plants and invertebrates (Cogoni and Macino, 1999; Dalmay et al., 2000; Mourrain et al., 
2000; Smardon et al., 2000; Sijen et al., 2001; Martens et al., 2002).  
1.4 MicroRNAs 
MicroRNAs are small, double-stranded RNA molecules po sessing the reverse complement 
of the mRNA transcript of another protein-coding gene. These miRNAs can inhibit the 
expression of the target gene. MiRNAs were first observed in C. elegans as RNA molecules 
of 18- to 23 nucleotides that are complementary to the 3' untranslated region of the target 
transcripts, including the lin-4 (Lee et al., 1993) and let-7 (Lau et al., 2001). As a result, 
these small RNA molecules regulated the development of he worm. Subsequently, 
miRNAs were found to occur in diverse organisms, ranging from worms, to flies, to 
humans (Lagos-Quintana et al., 2003), suggesting that these molecules represent a gene 
family that has evolved from an ancient ancestral gene.  
The miRNAs are thought to be transcribed from DNA that is not translated, but regulates 
the expression of other genes. Primary transcripts of he miRNA genes (pri-miRNAs) are 
long RNA transcripts consisting of at least one hairpin-like miRNA precursor. Pri-miRNAs 
are processed from the non-loop region in the nucleus into ~70 nucleotide hairpin-like 
precursor pre-miRNAs by a microprocessor (Lee et al., 2003).  
The core components of the microprocessor are the RNase III enzyme Drosha and a double 
stranded RNA binding protein termed DGCR8/Pasha (Lee et al., 2003; Denli et al., 2004; 
Gregory et al., 2004; Han et al., 2004; Landthaler et al., 2004). The pre-miRNAs are 
exported from the nucleus by Exportin-5 (Lund et al., 2004). The cytoplasmic RNase III 
enzyme, Dicer, excises the miRNA from the pre-miRNA loop region. MiRNAs and 









































Figure 1.2 miRNA Biogenesis: Shows Pri-miRNA processing by Drosha/DGCR8,    
translocation of pre-miRNA by Exportin5 into the cytoplasm where mature miRNA 
processed by Dicer. 
The annealing of the miRNA to the target mRNA inhibits protein translation (imperfect 
base pairing). In some cases, the formation of dsRNA through the binding of miRNA 
triggers the degradation of the mRNA transcript through a process similar to RNAi (perfect 
base pairing), although, in other cases, it was thoug t that the miRNA complex blocks the 
protein translation machinery or otherwise prevents protein translation without causing the 
mRNA to be degraded. Because most of the miRNA suppresses gene function based on 
partial complementarity, conceivably, one miRNA may t rget more than one mRNA, and 
many miRNAs may act on one mRNA, coordinately modulating the intensity of gene 





fine-tuning the protein-coding genes. Indeed, the discovery of miRNAs has revolutionized 
our understanding of gene regulation in the postgenome era. 
It has been observed that plant miRNAs follow the strategy of perfect complementarity 
while animal miRNAs primarily employ the latter mechanism (Vandenboom Li, 2008) (see 
Figure 1.3). The imperfect miRNA-mRNA complementarity in human cells is usually 
composed of matched nucleotides in the 5’ portion of the miRNA, termed the seed 
sequence (positions 2-7), with mismatches at positions 10 and 11 in the 3’ UTR of the 
transcripts (Elbashir et al., 2001a; Lewis et al., 2005; Berkhout and Jeang, 2007). In 
humans, this complex leads to the inhibition of target gene translation and only very rarely 
causes degradation of the mRNA.  
 
Figure 1.3 Modes of miRNA Action: A) complimentary base pairing of miRNA with 
mRNA, which results in the degradation of mRNAs, a common mechanism in plants. B)
imperfect base pairing of miRNA with mRNA results in translational inhibition, the typical 






1.4.1 MicroRNAs and cancer. 
When living cells exhibit abnormal growth and loss of apoptosis, it may result in cancer 
formation. Several recent studies indicate that miRNAs regulate cell growth and other 
cellular processes (Cheng et al., 2005). 
A more direct link between miRNA function and cancer pathogenesis was supported by 
studies examining the expression of miRNAs in clinial samples. The first study 
documenting abnormalities in miRNA expression in tumor samples focused on B-cell 
chronic lymphocytic leukemia (B-CLL). Deletion of chromosome 13q14 is the most 
frequent chromosomal abnormality in this disorder, and it has been postulated that a tumor 
suppressor gene resides in this region. It was demonstrated that this tumor suppressor 
activity is likely provided by two miRNAs, miR-15a and miR-16-1, which are localized in 
the minimally deleted region and are frequently deleted or downregulated in CLL patients 
(Calin et al., 2002).  
It was found that microRNA expression correlates with various cancers, and these 
regulatory genes are though to function as tumor suppressors or oncogenes (see Table 1). 
More than half of miRNAs are located at sites in the human genome which are frequently 
amplified, deleted, or rearranged in cancer, suggesting that miRNA abnormalities play a 
broad role in cancer pathogenesis (Calin et al., 2004). Also consistent with this notion, is 
the observed dysregulation of miRNA expression in diverse cancer subtypes including 
Burkitt’s lymphoma (Metzler et al., 2004), colorectal cancer (Michael et al., 2003), lung 
cancer (Takamizawa et al., 2004), breast cancer (Iorio et al., 2005), and glioblastoma (Chan 
et al., 2005). 
Recently, Golub and co-workers used a bead-based flow cytometric method to profile 217 
mammalian miRNAs across a large panel of samples repres nting diverse human tissues 
and tumors (Lu et al., 2005a). They found that miRNA profiles were highly informative, 





Furthermore, tumors within the same lineage harboring distinct chromosomal 
rearrangements were found to exhibit distinct miRNA expression profiles. Thus, the 
developmental history of a tumor is reflected by its miRNA expression pattern. 
Table.1: Examples of some microRNAs involved in cancer. 
miRNA Cancer Function References 
miR-15a, miR-16 Downregulated in B-cell chronic 




(Calin et al., 2002; Cimmino 
et al., 2005) 
miR-143,miR-145 Downregulated in colorectal 
cancers, breast, prostate 
Tumor 
suppressor 
(Michael et al., 2003; Iorio et 
al., 2005) 
miR-21 Upregulated in Glioblastoma and 
breast cancer 
Oncogenic (Ciafre et al., 2005; Iorio et 
al., 2005) 
Let-7 family Decreased in Lung cancer Tumor 
suppressor 
(Takamizawa et al., 2004; 
Johnson et al., 2005) 
Irrespective of cell type, more than half of the miRNAs examined in the Golub study were 
expressed at significantly lower levels in tumors compared with normal tissues. This likely 
reflects a role for miRNAs in terminal differentiation and the relatively incomplete 
differentiation status of cancer cells. Consistent with this hypothesis, inducing 
differentiation of a myeloid leukaemia cell line with trans- retinoic acid increased the 
expression of many miRNAs. A similar induction of miRNA expression was also observed 
in primary human haematopoietic progenitor cells undergoing erythroid differentiation. The 
emerging view from these studies is that deregulation of miRNA expression is a frequent 
occurrence in diverse types of cancer. These findings highlight the potential utility of 
miRNA profiling for diagnostic and prognostic applications. These studies also emphasize 
a need for more direct functional analyses of the rol s of miRNAs in regulating pathways 
relevant to tumor pathogenesis. 
Colorectal cancer is associated with alterations in miRNA expression where it was reported 





of colorectal cancer (Michael et al., 2003). miRNAs are also involved in brain cancer 
where Glioblastoma multiforme is the most frequent malignant brain tumor and these 
tumors are highly aggressive, invasive and one of the most incurable cancer in human 
(Ciafre et al., 2005). It was found by the same investigators, that miR-221 was strongly 
upregulated in glioblastoma samples from patients while miR-181a, miR-181b and miR-
181c were downregulated in glioblastoma compare to normal samples. 
MiR-372 and miR-373 were reported to function as oncogenes in human testicular germ 
cancers, which induce the proliferation and tumorgenesis of primary human cells that have 
both oncogenic RAS and active wild type p53 (Voorhoeve et al., 2006). 
1.4.2 MicroRNAs and apoptosis 
Apoptosis is a programmed, physiological mode of cell death that plays an essential role in 
tissue homeostasis. Deregulation of apoptosis is a critical step in cancer as it allows the 
genetically unstable cells to survive and accumulate further mutations that eventually lead 
to tumorgenesis. Multiple triggers of apoptosis are known, such as withdrawal of growth 
factors, DNA damage, Fas-ligand binding, or application of chemotherapeutic drugs 
(Collins et al., 1994; Berke, 1995). 
All of these triggers lead to cell death but they differ in the length of the period after which 
the cells shows the first morphological signs of apoptosis. This period is called trigger 
phase. The duration of this phase depends on the type of triggers, the cell type and the 
surrounding environment. Some genes were reported to control this phase, such as BCL2 
that protects the cells against apoptosis (Martin and Green, 1995; Nagata, 1997). 
It was reported that microRNAs play an important role in regulating the expression level of 
these genes such as the miR-15-16 cluster which induces apoptosis by targeting the anti-
apoptotic gene BCL2 at the translational level (Cimmino et al., 2005). Enhanced expression 





determined by Caspase activity, DNA fragmentation and nuclear condensation (Ostenfeld 
et al., 2010).  
It was demonstrated that miR-26a and miR-145 have an important role in TRAIL-induced 
apoptosis (Sudbery et al., 2010). 
MiR-21 was reported as the most upregulated miRNAs in many cancer types. miR-21 was 
established as an antiapoptotic factor by the observation that knock-out of miR-21 
increased apoptotic cell death in human glioblastoma cells (Chan et al., 2005). 
1.5 SiRNA delivery  
RNA interference has been regarded not only as an innovative approach to suppress the 
expression of a target gene, but also as a new therapeutic strategy to combat many diseases 
such as cancer, autoimmune diseases and viral infections (Iorns et al., 2007). SiRNAs and 
miRNAs can theoretically interfere with the expression of many genes through 
transcriptional or translational repression (de Fougerolles et al., 2007). Much progress has 
been made in clinical trials using siRNAs to treat many diseases such as age-related 
macular degeneration and respiratory syncytial virus infection (Melnikova, 2007). 
Moreover, the first evidence of targeted in vivo gene silencing for human cancer therapy 
through systemic delivery of siRNA using transferrin-tagged, cyclodextrin-based polymeric 
nanoparticles has been recently presented (Oh and Prk, 2009). 
The most important challenge in the use of siRNA-based therapies is the difficulty of 
delivery. Therefore, many strategies of siRNA delivry have been developed either in vitro 
or in vivo. Some strategies use viruses as natural vehicles while others use liposomes, 
nanoparticles or bacteria (transkingdom RNAi) (Li, 2006; Aigner, 2009; Kruhn et al., 2009; 
Nguyen and Fruehauf, 2009).  
Five types of viral vectors are currently in use for RNAi, including the Retrovirus, 





2005), and have been used efficiently to deliver siRNAs and induce gene silencing in a 
wide range of mammalian cells (Brummelkamp et al., 2002). Adenoviral vectors encoding 
siRNA against pituitary transforming gene 1, which lead to inhibition of the growth of the 
pituitary tumor in vitro and in vivo (Cho-Rok et al., 2006). Adeno-associated virus (AAV) 
has been approved as a promising and effective vector for nucleic acid delivery because of 
its non-pathogenecity and has a broad range of possible target cells, including non-dividing 
cells. It was reported that Adeno-associated virus ha been efficiently used for in vitro 
siRNA delivery (Tomar et al., 2003; Moore et al., 2005) as well as it has been used in vivo 
transfection via local stereotactic injection into the brain (Xia et al., 2004; Babcock et al., 
2005). 
Cationic liposomes formulated with anisamide-conjugated poly ethylene glycol penetrated 
effectively into lung metastases of melanoma tumors in mice and resulted in 70-80% gene 
silencing after a single intravenous injection (Lia SD, 2005). Chemically modified siRNA 
for enhanced RNA interference has been established, where several positions in siRNA 
have been modified or replaced in order to increase the efficiency of RNAi. For example, 
phosphodiester (PO4) linkages were replaced with phosphothioate at the 3′ end, and 
introducing O-methyl group greatly extended half-lives in plasma and enhanced RNAi 
efficiency in cultured cells (Braasch et al., 2003; Chiu and Rana, 2003; Czauderna et al., 
2003; Harborth et al., 2003). 
SiRNAs can be easily complexed with synthetic polymers e.g., polyethylenimine (PEI), 
biodegradable cationic polysaccharides, chitosan, and cationic polypeptides, atelocollagen 
or protamine, through electrostatic interactions. For example, an endothelial growth factor 
siRNA/atelocollagen complex significantly inhibited tumor angiogenesis and growth in 
prostate xenografts in mice (Takei et al., 2004). Intravenous injection of RhoA 
siRNA/chitosan complex resulted in effective gene sil ncing in subcutaneous breast cancer 
xenografts in mice (Pille et al., 2006). 
In order to achieve RNAi n vivo via systemic delivery, it is crucial for siRNA to be 





processes: prolonged circulation in the body, high accessibility to target tissues and specific 
binding to target cells. Targeted siRNA delivery maximizes the local concentration in the 
desired tissue and prevents nonspecific siRNA distribution. Recent studies have reported 
tumor-targeted siRNA delivery using nanoparticles that specifically bind to cancer-specific 
or cancer-associated antigens and receptors (Dubey et al., 2004; Lu et al., 2005b). 
Polyethylenimine is one of the most important nanoparticles used in nucleic acid delivery 
(Boussif et al., 1995). 
1.5.1 Polyethylenimine (PEI) 
Polyethylenimine (PEI) is one of the most widely examined synthetic cationic polymers for 
nucleic acid delivery in vitro and in vivo. Polyethylenimines are synthetic linear or 
branched polymers available in a wide range of molecular weights (Tang and Szoka, 1997; 
Godbey et al., 1999). PEI is very efficient in nucleic acid deliv ry with its distinctively high 
buffering capacity at endosomal pH ‘proton sponge eff ct’ which releases ‘the nucleic acid 
payload’ into the cytoplasm (Boussif et al., 1995).  
PEI exists as branched or linear morphological isomers. Branched polyethylenimine (bPEI) 
has been used to deliver oligonucleotides (Bandyopadhyay et al., 1999), plasmid DNA 
(Iwai et al., 2002) as well as RNA and intact ribozymes (Aigner et al., 2002). The efficacy 
of branched-PEIs as non-viral vehicles and their cytotoxic effects depend on material 
characteristics like the molecular weight, the degre  of branching, the cationic charge 
density and buffer capacity (Fischer et al., 1999; A. von Harpe, 2000; Kunath et al., 2003) 
The efficiency of transfection is depending on some factors e.g. the N/P ratio, which refers 
to the ratio of the nitrogen atoms of PEI to nucleic acid phosphates and simply describes the 
amount of polymer used for polyplex formation (Lungwitz et al., 2005). The N/P ratio 
influences the efficiency of the nucleic acid delivry, it has been shown that every fifth or 





these positively charged amino groups can interact with the negative charge of nucleic 
acids. Therefore at high N/P ratio and the positive net charge of the corresponding 
complexes increases, which leads to improvement of cell interaction and enhancement of 
the cellular and nuclear uptake (Oh et al., 2002). Particle size of the polyethylenimine plays 
an important role in efficacy of transfection process, which can be controlled by the N/P 
ratio, the molecular weight and during the particle pr paration (Ogris et al., 1998).  
In contrast to branched-PEI, linear polyethylenimine (l-PEI) is characterized by presence of 
all secondary amino groups within the random copolymers which increase the buffering 
capacity and enhance the nucleic acid compaction (Lu gwitz et al., 2005), while b-PEI 





Fig 1.4. Chemical structure of linear-PEI and branched-PEI 
Figure 1.4: Chemical structure of linear-PEI and branched-PEI 
It was shown that l-PEI is an efficient transfection agent in vitro and ex vivo (Louis et al., 
2006). In this study, they proved that intraperitoneal injection of ovarian tumor nodes 
developed in mice with l-PEI/DNA complex led to straightforward distribution of plasmid 






In vivo studies, in xenografted mice, have established that intr periotoneal injection of PEI-
complexed siRNAs lead to delivery of intact siRNAs into subcutaneous tumors and 
efficient suppression of tumor growth as illustrated in studies carried out by (Urban-Klein 
et al., 2005). 
Polyethylenimine complexes with the nucleic acids in an anionic interaction and introduce 
them into a variety of different cells via endocytosis (Klemm et al., 1998).  
Proton sponge hypothesis was postulated by (Behr, 1994), where it allows the osmotic 
swelling of endosomal vesicles which lead to rupture of the vesicles and release of the 
PEI/complex in the cytoplasm. 
 
 








2. Objectives of the thesis 
The aims of this work were to study the non-viral delivery of microRNA in colon cancer in 
vitro and in vivo. To this end, this thesis focused on the following points:  
 
1- Selection of appropriate microRNAs that are already known to be downregulated in 
colorectal cancer. This step was done by searching several databases such as 
http://www.targetscan.org/, http://www.microrna.org/microrna/home.do. 
 
2- Evaluation of the expression level of the mature and precursor forms of miR-143 and 
miR-145 in different cell lines of different origins.  
 
3- Establishment of in vitro miRNA delivery by different transfection reagents through 
variations in transfection conditions. 
 
4- Analysis of cellular effects of miR-143 and miR-145 delivery in colon cancer cells 
(proliferation assay, apoptosis assay, soft agar assay, biochemical and immunochemical 
analysis). 
 
5- Evaluation of the antitumor effects of Polyethylenimine (PEI)-mediated miR-145 delivery 
in vivo using athymic nude tumor xenograft models. 
 
      6- Analysis of cellular effects of the therapeutic miRNA replacement in vivo in the s.c tumor  
          xenografts.
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  3. Materials and Methods 
3.1 Materials 
3.1.1 Reagents 
Standard chemicals and reagents were purchased from well-known companies. 
Name                                                                                                                     Supplier 
Ammonium Peroxodisulfate (APS)                                                                      Merck 
Bacto-Agar                                                                                                              Becton 
BromphenolBlue                                                                                                         ROTH 
BSA                                                                                                                       ROTH 
Cell Proliferation Reagent WST-1                                                                        Roche 
3,3’-Diaminobenzidinetetrahydochloride (DAB)                                        SIGMA-Aldrich 
Diethylpyrocarbonate (DEPC)                                                                    SIGMA-Aldrich 
Harris hematoxylin solution                                                                      SIGMA-Aldrich 
Jet-PEI                                                                                                                     Polyplus     
PEI F25-LMW (LMW 4-10 kDa)                                   fractionated and purified in the lab 
INTERFERinTM                                                                                                 Polyplus 
2-Mercaptoethanol                                                                                SIGMA-Aldrich 
Milk powder                                                                                                SIGMA-Aldrich 
Normal goat serum                                                                                               Vector 
Normal horse serum                                                                                                   Vector 
N,N,N',N',-Tetramethylethylendiamine (TEMED)                                     SIGMA-Aldrich 
Prestained protein ladder, 11-250 kDa                                                               Fermentas 
RotiPhorese® Gel 30                                                                                                  ROTH 
Trizol Reagent                                                                                            SIGMA-Aldrich 
Tween 20                                                                                              SIGMA-Aldrich 
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3.1.2 Kits and enzymes 
Name                                                                                                                    Supplier 
mirVanaTM microRNA isolation kit                                                                   Ambion 
LumiGlo HRP Western blot kit                                                                       Amersham  
DC protein assay                                                                                                Bio-Rad 
Caspase-Glo® 3/7 assay                                                                                         Promega 
RevertAid™ H Minus First Strand cDNA synthesis kit                                          Fermentas 
RevertAid™ H Minus Reverse Transcriptase  
RiboLock™ RNase inhibitor  
5X Reaction buffer  
dNTP Mix, 10 mM each 
ABsoluteTM QPCR SYBER® GREEN Capillary MIX                              Thermo Scientific 
FITC Annexin V apoptosis detection kit I                                              BD Pharminge ™ 
10X annexin V binding buffer 
FITC annexin V 
Propidium iodide staining solution 
 
3.1.3 Antibodies  
Name                                                                                                                  Supplier  
Rabbit polyclonal C-Myc antibody          Santa Cruz Biotechnology 
Rabbit polyclonal ERK5 antibody      Cell Signaling 
Rabbit polyclonal β-actin antibody                                              Santa Cruz Biotechnology 
Anti-Rabbit IgG horseradish peroxidase linked antibody                                  GE Healthcare 
Biotinylated horse anti-mouse IgG antibody                                               Vector laboratories 




Materials and Methods 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
25 
3.1.4 Oligonucleotides and primers 
Name                                                                                                                 Sequence  
hsa-miR-143 for                                                   5'-GGUGCAGUGCUGCAUCUCUGGU-3' 
hsa-miR-143 rev                                               5'-UGAGAUGAAGCACUGUAGCUC-3' 
hsa-miR-145 for                                                 5'-GUCCAGUUUUCCCAGGAAUCCCU-3' 
hsa-miR-145 rev                                            5'-GGAUUCCUGGAAAUACUGUUCU-3'  
ERK5 for                                                                      5'-AATGGCGGACACAATTCC-3' 
ERK5 rev                                                                   5'-GCCGTCTTCCTCCTTCAGA- 3' 
c-Myc for                                                                          5'-CACCAGCAGCGACTCTGA-3' 
c-Myc rev                                                           5'- GATCCAGACTCTGACCTTTTGC-3' 
PCNA for                                                            5'-TGGAGAACTTGGAAATGGAAA-3' 
PCNA rev                                                     5'- GAACTGGTTCATTCATCTCTATGG-3' 
Actin for                                                                      5'-CCAACCGCGAGAGAGTA -3' 
Actin rev                                                               5'- CCAGACGCGTACAGGGATAG-3' 
Stem loop RT primer miR-145            
   5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGGATT-3' 
hsa-miR-145 for                                                        5'-CGCGCGTCCAGTTTTCCCAGG-3' 
Stem loop RT primer miR-143                 
     5'-CGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGAGCTAC-3' 
hsa-miR-143 for                                                          5'-CGCGCGTGAGATGAAGCACT-3' 
Universal Reverse PCR Primer                                       5'-GTGCAGGGTCCGAGGT-3' 
 
3.1.5 MicroRNAs 
Name                                                                                                                 Sequence  
hsa-miR-143 for                                                     5'-GGUGCAGUGCUGCAUCUCUGGU-3' 
hsa-miR-143 rev                                                 5'-UGAGAUGAAGCACUGUAGCUC-3'  
hsa-miR-145 for                                                  5'-GUCCAGUUUUCCCAGGAAUCCCU-3' 
hsa-miR-145 rev                                              5'-GGAUUCCUGGAAAUACUGUUCU-3' 
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3.1.6 Tissue culture media and reagents 
Name                                                                                                                      Supplier 
IMDM + Glutamine                                                                                                         PAA 
Fetal Calf Serum (FCS)                                                                                           Gibco 
Trypsin/EDTA                                                                                                                 PAA 
Phosphate buffered Saline (PBS)                                                                                     PAA 
Keratinocyte SFM with Glutamine                                                                             Gibco 
 
3.1.7 Cell lines 
Cell Line Tissue Cell Type Source 
A549 Lung Adenocarcinoma ATCC 
K562 Bone marrow Chronic myelogenous leukemia ATCC 
SKOV3 Ovary Adenocarcinoma ATCC 
OVCAR-3 Ovary Adenocarcinoma ATCC 
DU145 Prostate Adenocarcinoma ATCC 
PC3 Prostate Adenocarcinoma ATCC 
HCT116 Colon Colorectal carcinoma ATCC 
SW620 Colon Colorectal adenocarcinoma ATCC 
SW480 Colon Colorectal adenocarcinoma ATCC 
LS180 Colon Colorectal adenocarcinoma ATCC 
LS174t Colon Colorectal adenocarcinoma ATCC 
LoVo Colon Colorectal adenocarcinoma ATCC 
Colo201 Colon Colorectal adenocarcinoma ATCC 
U87 Brain Glioblastoma ATCC 
1205LU Skin Melanoma ATCC 
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 3.1.8 Devices and working materials 
Name                                                                                                                    Supplier 
Adjustable air-displacement pipettes Pipetman®                                                         Gilson 
Autoclave Varioklav®                                                                                  H+P Labortechnik 
Balance ERN572                                                                                         KERN&Sohn 
Centricon-10 vials                                                                                                       Amicon 
Centrifuge Biofuge                                                                                                Heraeus 
Centrifuge Megafuge 1.0 R                                                                                  Heraeus 
Centrifuge Sorvall RC 5B                                                                                          Du Pont 
CO2-incubator Hera Cell                                                                                            Heraeus 
Digital Camera Digital Science DC 120                                                           Zoom Kodak 
Dounce homogenizer                                                                                                 B.Braun 
ELISA reader                                                                                                           BIO-TEK 
Exposition cassette (Hypercassette™)                                              Amersham Pharm cia 
FLUOstar OPTIMA                                                                                  BMG LABTECH 
FACSCalibur                                                                                        Becton-Dickinson 
Heat block                                                                                                                   PeQLab 
Hyperfilm ECL                                                                                     Amersham Pharmacia 
Laminar flow hood Hera Safe                                                                              Heraeus 
Light microscope Wilovert A                                                                                        Hund 
Light cycler                                                                                    Roche Diagnostics, Penzberg 
Magnetmixer Variomag®                                                                               H+P Labortechnik 
PCR T3 thermal cycler                                                                                      Biometra 
pH-meter                                                                                              GREISINGER Electronic 
Orbital shaker                                                                                                Forma Scientific 
Power supply PAC300                                                                                       Bio-RAD 
PVDF 0.45um membrane                                                                    Schleicher & Schuell 
-80°C freezer                                                                                           Forma Scientific 
Rotor SS-34                                                                                                            Sorvall 
Ultracentrifuge L7-55                                                                                          Beckman 
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UV-Bank UV Transilluminator 2000                                                                        Bio-Rad 
Vortex                                                                                                         Janke&Kunkel 
 
3.1.9 Standard solutions and buffers  
Name                                                                                 Components and Concentration  
Cell culture freezing medium 
DMSO                                                                                                                 5% (w/v) 
FCS                                                                                                                         2 0% (v/v) 
IMDM ad 100% (v/v) 
=================================================== ============= 
10x PBS (Phosphate-buffered saline) 
NaCl                                                                                                                         1.5 M 
Na2HPO4                                                                                                                52 mM 




NaCl                                                                                                                     150 mM 
Na2HPO4                                                                                                               5.2 mM 
KH2PO4                                                                                                                 1.7 mM 




Tris-HCl                                                                                                                          1 M 
NaCl                                                                                                                        1.5 M 




SDS                                                                                                                         4 % (v/v) 
2-Mercaptoethanol                                                                                          40 % (v/v) 
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Glycerol                                                                                                           20 % (v/v)  
Bromphenol blue                                                                                        0.01 % (w/v) 
=================================================== =============
10x SDS electrophoresis buffer 
 
Tris-HCl                                                                                                            2.9 % (w/v) 
Glycine                                                                                                        14.4 % (w/v) 
SDS                                                                                                                       1 % (w/v) 
=================================================== =============
10x transfer buffer  
 
Tris-HCl                                                                                                             2.9 % (w/v) 
Glycine                                                                                                        14.4 % (w/v) 
pH adjusted to 8.5 
=================================================== =============
10x Western blot electrophoresis transfer buffer 
 
Tris-HCl                                                                                                             2.9 % (w/v) 
Glycine                                                                                                       14.4 % (w/v) 
pH adjusted to 8.5 
=================================================== =============
Western blot stripping buffer 
 
Glycine                                                                                                                     0.1M 
pH adjusted to 2.9 
=================================================== ============= 
1XCell Lysis buffer 
 
Tris-HCl                                                                                                                        20 nM 
NaCl                                                                                                                   150 mM 
EDTA                                                                                                                     1 mM 
Triton X-100                                                                                                           1% (v/v) 
Sodium pyrophosphate                                                                                     2.5 mM 
NP40                                                                                                                       1 % (v/v) 
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SDS                                                                                                                     0.1% (w/v) 
PMSF immediately prior to use                                                                            1 mM 
Complete mini EDTA free Protease inhibitor cocktail 




Milk powder                                                                                            5% (w/v) in TBST 
=================================================== =============
Primary Antibody Dilution Buffers 
 
BSA                                                                                                    5% (w/v) in TBST 
Milk powder                                                                                      5% or 3% (w/v) in TBST 
=================================================== =============
Secondary Antibody Dilution Buffer                              
 













3.2.1 Cell culture  
All cell lines were cultured in 75 cm2 flasks in Dulbecco’s modified Eagle’s medium 
supplemented with glutamine 10% fetal calf serum, with the exception of 1205LU, which 
were maintained in Keratinocyte SFM supplemented with Glutamine and 10% fetal calf 
serum. Handling and propagation of all cell lines were done under sterile conditions. All 
solutions were stored at 4°C and pre-warmed to 37°C in a water-bath prior to use.  All cell 
lines were grown under standard conditions (37°C, 5% CO2) in a humidified incubator. 
3.2.2 Freezing and Thawing of cultured cell lines 
To store the cell lines for long term, it was recommended to dilute them in freezing medium 
and to keep them at –80°C or in liquid nitrogen. Cells were harvested (at least at 80 % 
confluency) and centrifuged at 1000g for 5 min. The m dia was then aspirated and the cells 
were resuspended in 1.5 ml of cell culture freezing medium (IMDM culture medium, 20% 
FCS and 5% DMSO). The resuspended cell solution was tran ferred to cryo-tubes and placed 
at –80°C in an isopropanol-containing cell-freezing container, which guarantees a slow 
freezing process. After 24 h, the tubes were transferred to a storage box at –80°C or in liquid 
nitrogen. 
To grow up a cell line, the freeze stock of the cells was thawed quickly in a 37oC water-bath 
then, added to 5ml fresh medium and centrifuged at 800g for 10 min to get rid of the traces 
of the cryoprotectanct (DMSO). Then, the supernatant medium was aspirated and a fresh 
growth medium was immediately added to the pellet, and the suspension was transferred to a 
culture flask containing 10 ml medium and incubated un er standard conditions (5% CO2, 
37°C). 
 
Materials and Methods 
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3.2.3 Maintenance of cells in culture 
All cell lines were grown in a 37°C, 5% CO2 incubator and split in certain ratios depending 
on the stage of confluency and the proliferation rate of each cell line. The medium was 
changed every three days (according to the confluency). To split the cell lines, the medium 
was completely aspirated from the flask and the cells were washed briefly with 5-10 ml of 
PBS to remove traces of FCS. After removing the PBS, 2 ml trypsin was added to the flasks 
and then incubated at 37°C. The cells were detached aft r about 1-2 min with occasional 
gentle tapping. The trypsin was then immediately inactivated by adding 8 ml of serum-
containing medium to each flask. This suspension was tr nsferred into a 15 ml tube and 
centrifuged at 1000g for 5 min. The supernatant was aspirated and the cell pellet was 
resuspended in medium and split into new flasks. The amount of medium added to the flask 
was dependent on its size. For 75 cm2 flasks, 10 ml medium was added 
3.2.4 Cell Transfection  
Transient transfections were performed using Jet-PEI, I F25-LMW and INTERFERin as 
tranfection reagents. Each reagent has its own protocol of transfection as indicated by the 
manufacturers. Prior to transfection, cells were grown to 50-70% confluency in culture flasks 
in 10ml IMDM medium containing 10 % FCS.  
The cells were seeded on the day before transfection in 96-well plates and the complexes 
were added subsequently to the cells. The transfection was done according to the type of the 
reagents where Jet-PEI was used at (N/P ratio 5), PEI F25-LMW was used at (N/P ratio 33) 
while INTERFERin was added in (a volume manner) as follows. 
 
 
Materials and Methods 
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for 20 wells 
Volume of   
Jet-PEI + 
HEPES/NaCl 




96-well 1000  100 ul 2 µl +200 µl 2.6 ul+200 µl 120 µl 
6-well 200-300x103 2 ml 2 µl+ 50 µl 
(for one well) 
2.6 µl+50 µl 2.1 ml 










for 20 wells 







96-well 1000 100 µl 10 µl +200 µl 0.13 µl+   200 µl 120 µl 
6-well 200-300x103 2 ml 2 µl+ 50 µl 
(for one well) 
0.13 µl+50 µl 2.1 ml 







Amount of miRNA+ 
medium without serum 
+INTERFERin 




96-well 1000 100 µl 0.8 µl + 1000 µl+ 8 µl 150 µl 
6-well 200-300x103 2 ml 8 µl+ 200 µl + 10 µl 






Materials and Methods 
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3.2.5 In Vitro analysis 
3.2.5.1 Anchorage-dependent proliferation assay 
The measurement of cell proliferation and cell viabil ty has become a key technology in life 
science. A proliferation assay has become available for analyzing the number of viable cells 
by cleavage of the tetrazolium salt (WST-1: 4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate) added to the culture medium. This technique requires 
neither washing nor harvesting of cells and the complete assay from the beginning to 
measurement by ELISA reader was performed in the same plate. 
The principle of this assay is that the tetrazolium salt is cleaved to form a water-soluble 
formazan red dye by cellular enzymes (mitochondrial dehydrogenases). The soluble 
formazan produced by metabolically active cells was quantified through a scanning in a 
multiwell spectrophotometer (ELISA reader) by measuring the absorbance of the dye at 
450nm. 
The determination of anchorage-dependent proliferaton of LS174t and HCT-116 was carried 
out in a humidified incubator under standard conditions. LS174t cells were seeded in 
triplicates in 96-well plates at 1000 cells per well on the day before transfection (100 µl 
IMDM culture medium supplemented with 10% FCS, while HCT-116 were seeded at 200 to 
300 cells per well in the same medium. 
The cell density was measured at various time points (4 - 5 days) to obtain a growth curve.  
At the time of measurement, the medium was aspirated nd the WST-1 was diluted in IMDM 
culture medium 1:10 and 50 µl was added to each well and incubated for 1 h at 37°C  in 5% 
CO2 humidified incubator. For measuring the background, an empty well was filled with 50 
µl diluted WST-1 at every time point. 
 
Materials and Methods 
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3.2.5.2 Anchorage-independent Proliferation assay 
The anchorage-independent growth assay (soft agar assay) resembles more closely the in 
vivo conditions since the transformed cells have the ability to form three-dimensional 
colonies in soft agar. 
LS174t and HCT116 cells were seeded in 6-well plates t 200-300x103 per well on the day 
before transfection. The LS174t cells were transfected with 100 nM miRNAs using JET-PEI 
while HCT-116 were transfected with 20nM miRNAs using INTERFERin as transfection 
reagent, the cells were then incubated for 24 h in 37°C, 5% CO2 humidified incubator.  
Before doing the experiments, 2.4% agarose was prepared (2.4 g Bacto-agar was dissolved in 
100 ml mono-distilled water and autoclaved).  
In the laminar flow, a water bath at 42°C was prepad in which an empty sterilized 50 ml 
bottle was placed with 1.25 ml 10x IMDM-medium and 37.5 ml 1x IMDM-medium with 
10% FCS.   
The 2.4% agarose was melted completely in a microwave and then cooled to about 50°C. 
Then 12.5 ml was added to the bottle in the water bath (resulting in a final agarose 
concentration of 0.6%). 
1 ml of 0.6 agarose solution was pipetted into a well of a 6-well plate (bottom layer), air 
bubbles were avoided, and the plates were then allowed to cool and solidify.  
During solidification of the bottom layer, the cells were trypsinized, harvested, counted and 
adjusted to 6x104 cells/ml.  
In a 12-well plate, 1 ml of this cell suspension was mixed with 1.5 ml of the 0.6 % agrose 
mixture was added to the same well. 
Materials and Methods 
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Then 800 µl (about 20x103 cells per well) of this mixture was immediately overlaid on the 
bottom layer of 6-well plates (the experiment was done in triplicates). 
Depending on the cell line, the plates were incubated 1-3 weeks at 37°C, 5% CO2 in a 
humidified incubator. Colonies larger than 50 µm in diameter were counted independently by 
two blinded investigators.  
3.2.6 Biochemical and immunochemical methods  
3.2.6.1 Protein and measurement of protein concentration 
To analyze expression level of our targets at the protein level, transient transfections were 
performed as described above in LS174t and HCT-116 with 100 nM or 20 nM miRNAs, 
respectively. At 96 h post transfection, cells were lysed by addition of 200 µl denaturating 
lysis buffer, sonicated for 20 sec, then incubated on ice for 30 min and then centrifuged at 
13,000 rpm for 25 min. The supernatant was pipetted into a new tube and stored at -20°C.  
The protein concentration in  lysates either from cell lines or from tumor xenografts were 
measured by the Bio-Rad DC protein assay kit by Elisa Reader at 630 nm using standard 
curve of different concentration of bovine albumin as standard. Measurement of protein 
concentration was performed in 96-well plates in triplicates and in comparison to a blank as 
following: 
10 µl sample (cell or tumor lysate) 
20 µl solution A* (1 ml solution A + 20 µlsolution S) 
Mix well, then 
100 µl solution B 
Incubation for 15 min. 
Before electrophoretic separation, the tertiary structure of protein was denatured through 
thermal denaturation at 95°C in SDS-containing sample loading buffer. By Addition of this 
anionic detergent, the protein chains were covered with negative net charge.  
Materials and Methods 
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SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
blotting 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is used to separate 
complex protein mixtures by their molecular size. The standard Laemmli method is applied 
for discontinuous gel electrophoresis under denaturing conditions in the presence of SDS. 
Western blotting (immunoblotting) is applied to identify specific proteins (antigens) 
recognized by polyclonal or monoclonal antibodies. After separation by SDS-PAGE, the 
proteins are electrically transferred onto PVDF membranes. The transferred proteins are 
bound to the surface of the membrane providing access for immunodetection reagents.  
All remaining binding sites are blocked by immersing the membrane in a solution containing 
either a protein or a detergent-based blocking agent. After probing with the primary 
antibody, the membrane is washed and the antigen is identified by detection with a secondary 
horseradish peroxidase-conjugated anti-IgG antibodies. Visualization of the antigen/antibody 
complex is performed by enhanced chemiluminescence using sensitive light-films.  
Sample preparation 
According to the protein concentration, 100 µg of protein lysate was mixed with 4x SDS 
loading buffer then diluted to 1x by adding distilled sterilized water. Then the samples were 
incubated in a hot plate at 90°C for 5 min. 
Preparation of SDS gels. 
Separation gel 7% 3.5 ml 30% acrylamid/0.8% bis-acryl mide 
3.75 ml 4x Tris-HCl/SDS, pH8.8 
7.75 ml H2O 
50 µl 10%(w/v) ammonium persulphate (APS) 
10 µl TEMED (N,N,N,N-Tetramethylendiamin) 
Stacking gel 4% 1ml 30% acrylamid/0.8% bis-acrylamide 
1.25 ml 4x Tris-HCl/SDS, pH8.6 
3.05 ml H2O 
50 µl 10% (w/v) ammonium persulphate (APS) 
20 µl TEMED (N,N,N,N-Tetramethylendiamin) 
Materials and Methods 
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The separation gel solution was prepared and mixed well. It was poured between the glass 
plates and then overlaid with isopropanol to straighten and even the level of the gel. After 
polymerization, the isopropanol was aspirated, the stacking gel was added and a suitable 
comb was directly inserted. 
For c-Myc, a 15 % gel was performed. 
Electrophoresis and Western Blot 
The comb was carefully removed from the gel cassette and the whole gel was placed in a 
chamber filled with an adequate volume of gel running buffer. 40 µg of denatured protein 
was injected smoothly, using a suitable syringe, into the wells. Likewise, in one lane a 
protein ladder (11-250 kDa) was added. The gel was run for at 200V until the 
bromophenolblue reached the end of the gel.  
The gel was removed from the apparatus and the upper stacking gel was discarded, and the 
separation gel was incubated in about 100 ml transfer buffer for 5 min with shaking. In the 
mean time, one piece of PVDF per gel cut to the sizof the gel, was incubated in methanol 
for 1 min, washed in bidistilled water and then incubated in 100 ml transfer buffer for at least 
10 min. 
 
Separation gel 7% 7.5 ml 30% acrylamid/0.8% bis-acryl mide 
3.75 ml  4x Tris-HCl/SDS, pH 8.8 
3.75 ml H2O 
50 µl 10%(w/v) ammonium persulphate (APS) 
10 µl TEMED (N,N,N,N-Tetramethylendiamin) 
Stacking gel 4% 1ml  30% acrylamid/0.8% bis-acrylamide 
1.25 ml 4x Tris-HCl/SDS, pH8.6 
3.05 ml H2O 
50 µl 10% (w/v) ammonium persulphate (APS) 
20 µl TEMED (N,N,N,N-Tetramethylendiamin) 
Materials and Methods 
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The transfer sandwich was prepared in the following order from the negative cathode to the 
positive anode. 
Three pads wetted in the transfer buffer 
Three wetted filter papers 
The gel 
The PVDF membrane 
Three wetted filter papers 
Three wetted pads  
The transfer cassette was tightly put into the transfer chamber, while was filled with 1X 
transfer buffer. The transfer was performed for 90 min. The PVDF membrane was then 
removed. Optionally, it was incubated in Ponseau S solution (0.1 % ponceau S (w/v) in 5 % 
acetic acid (v/v) for 30 sec to check the efficiency of blotting process, and then washed under 
tap water several time to remove the stain remaining. 
The membrane was then incubated in blocking solution (5 % non-fat dry milk in 1X TBST) 
for one hour at room temperature with shaking.  
The blot was washed three times 5 min each, and then incubated in the primary antibody 
dilution at 4°C overnight (1:1000 for ERK5 and 1:500 for c-Myc). It was then washed three 
times 5 min each in TBST and incubated in a 1:2000 dilution of donkey anti-rabbit 
secondary antibody coupled to horseradish peroxidase for 1 h at RT. After additional 
washing steps in TBST as above, bound antibody was visualized as bands using the 
enhanced chemiluminescence reagents system from Amersham at different exposure times. 
3.2.6.2 Immunohistochemistry 
This experiment was performed over two days, using a standard streptavidin 
biotinperoxidase complex method. On first day The tumor sections (3 µM thickness) were 
firstly deparaffinized by immersing them two times in Xylol for 10 min each, then 
Materials and Methods 
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rehydrated by washing  in 100% ethanol two times 5 min each and then 2 min for one time in 
a gradual concentrations of ethanol (90%, 80%, 70%). The slides were washed for 1 min in 
bi-distilled water and then washed one time for 5 min in phosphate buffered saline-Tween 
(PBST).  
For antigen retrieval, the slides were immersed in a 90°C 1% acetic acid (v/v PBS) for 15-20 
min. The slides were left to cool down for 20 min at room temperature then washed in PBST 
for 5 min.  
For blocking endogenous peroxidase, the slides were incubated in 3% peroxide solution    
(10 ml 30% H2O2 to 90 ml ddH2O) at 4°C for 30 min; the slides were washed three tim s in 
PBST for 5 min each. Manually the slides were dried an  carefully the surrounding area 
around the tumor sections. By a grease pencil, a thick circle was lined around the sections to 
prevent the leakage of subsequent added solutions.  
For blocking of the non-specific sites on the sections, 100-200 µl of blocking solution    
(10% horse serum in 1X PBST and 2% BSA) was added, the blocking solution which was 
used was from the species the secondary antibody was derived from, and incubated for one h 
at room temperature. The blocking solution was aspir ted (not washed) and directly (avoid 
dryness) 100 µl of the primary antibody dilution 1:400 (diluted in PBST and 2% BSA) was 
added. The slides were incubated in a humidified chamber overnight at room temperature.  
On the second day, the slides were washed three times 5 min each, then the secondary 
antibody was added which was diluted in PBST and 2% BSA at 1:3000 and incubated for 
one h at room temperature.  
The slides were washed three times in PBST 5 min each. During washing step, the 
avidin/biotin complex (ABC) was prepared as follow (10 ml PBST+ 2 drops avidin and 
vortex well and then 2 drops biotin and vortex). The ABC was added to the section and 
incubates for 30 min at room temperature. During last 5 min of incubation, the 3,3’-
diaminobenzidine (DAB) solution was prepared (250 mg DAB was dissolved in 50ml 
Materials and Methods 
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ddH2O), 180 ml PBST and 20 ml 1M Tris-HCl pH 7.5 was adde , then 25 µl H2O2 was 
added just before use.  
Before doing staining step, the slides were washed in PBST three times 5 min each, and then 
the slides were incubated at room temperature in DAB solution for adequate time to get 
enough staining. The staining was stopped by immersing the slides in ddH2O. The slides 
were counter-stained by a blue hematoxylen for 30 sec to one min. Then the slides were 
washed in tap water for 5 min and checked under micoscope.  
The slides were mounted with organic mounting media but previously the slides were 
dehydrated by immersing them in gradual concentrations of ethanol but in reverse manner 
(i.e.; 70%, 80%, 90% and 100%), then in Xylol for 10 min, the slides were well dried, the 
mounting media was added and finally covered by a glass cover. 
3.2.7 Apoptosis analysis 
3.2.7.1 Caspase Glo3/7 assay 
The Caspase-Glo® 3/7 Assay is a homogeneous, luminesce t assay that measures caspase-3 
and -7 activities. These members of the cysteine aspartic acid-specific protease (Caspase) 
family play effective roles in the apoptosis process in mammalian cells.  
This assay was measured at various time points (24, 72 and 120 h) after miRNA transfection 
of cells.  
The cells were seeded in a 96 well plates. The media was aspirated and 100 µl of fresh 
Caspase-Glo® 3/7 Reagent to each well. In addition, 100 µl of fresh caspase reagent was 
measured in an empty well as a blank.  
The plates were incubated for 1 h at room temperature in the dark. The caspase level was 
measured in a plate reading luminometer.  
Materials and Methods 
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In parallel, the number of viable cells was determined by a WST-1 assay as described above.  
The readings of caspase levels in each well were nomalized to the values of viable cells as 
determined by WST-1. 
3.2.7.2 FITC-Annexin assay 
This assay provides a simple and efficient method to etect apoptosis at a very early stage. It 
takes advantage of the fact that phosphatidylserine (PS) is translocated from the inner 
(cytoplasmic) leaflet of the plasma membrane to the out r (cell surface) leaflet soon after the 
induction of apoptosis, and that the annexin V protein has a strong, specific affinity for PS. 
Phosphatidylserine on the outer leaflet is then avail ble to bind labeled annexin V, providing 
the basis for a simple staining assay. 
The LS174t cells were seeded and transfected in 6-well plates with miRNAs as described 
above. The cells were harvested after 120 h, were washed twice with cold PBS and 
resuspended in 1X Binding buffer at a concentration 106 cells/ml. 100 µl were transferred to 
a new Eppindorf tube, 5 µl FITC-annexin and 5 µl of propedium iodide were added, the 
mixture was gently vortexed and incubated for 15 min at room temperature in the dark. 
Directly before measurement, 400 µl 1x binding buffer was added and the suspension was 
measured within 1 h by FACS. 
3.2.8 Molecular biology methods 
3.2.8.1 Isolation of microRNA 
 To isolate microRNA, the mirVanaTM miRNA isolation kit was used for purification 
of RNAs suitable for studies of both siRNA and miRNA in natural populations. This method 
employs an organic extraction followed by immobilizat on of RNA on glass-fiber filters to 
Materials and Methods 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
43 
purify either total RNA, or RNA enriched for small RNA species from cells or tissue 
samples. 
Adherent cells were washed with PBS and trypsinized, then inactivated and pelleted. The 
pellets were washed with 10 ml PBS, centrifuged again and the supernatant was aspirated.  
300–600 µl of lysis-binding buffer was added (to lyse the cells). The cells were lysed 
immediately and vortexed vigorously to completely lyse the cells and to obtain a 
homogenous lysate. In case of tumor tissue, the lysis-binding buffer was added as 10 
volumes to the weight of the tumor. 
To the homogenous lysate, a 1/10 volume of miRNA Homogenate Additive was added and 
mixed well by vortexing, and the mixture was left on ice for 10 min. 
A volume of acid-phenol chlorophorm that is equal to the lysate volume before addition of 
miRNA homogenate was added and vortexed for 30-60 sec. 
The mixture was centrifuged for 5 min at maximum speed at room temperature to separate 
the aqueous and organic phases. The aqueous (upper) lay r was carefully removed without 
disrupting the lower layer and transferred to a fresh tube (the removed volume was exactly 
measured). 
One-third volume (1/3) 100% ethanol was added to the aqueous phase recovered in the 
previous step and was mixed by vortexing or inverting he tube several times. 
For each sample, a filter cartridge was placed into one of the collection tubes. The aqueous 
phase-ethanol mixture was pipetted onto the filter (fo volumes more than 700 µl, the 
mixture was supplied in successive steps to the same filter). 
The collection tubes were centrifuged for 15 sec at m ximum speed to pass the mixture 
through the filters and the filtrate was collected for the next step. 
Materials and Methods 
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Two-third (2/3) volume 100% ethanol was added to the filtrate, mixed well and pipetted onto 
a new filter cartridge, then centrifuged for 15 secat maximum speed. 
The filtrate was discarded and this step was repeatd several times until all of the 
filtrate/ethanol mixture had passed the filter. 
The previous collection tube was used in the following washing step where 700 µl of 
miRNA wash solution 1 was applied to the filter and centrifuged for 15 sec at maximum 
speed, then followed by another two washing step by application of 500 µl of miRNA wash 
solution 2/3 and centrifuged as indicted above. 
The filter cartridge was transferred to a new collection tube and 100 µl pre-heated (95°C) 
Elution Solution was added to the filter and centrifuged for one minute at maximum speed. 
The collection tubes containing the small RNA including microRNA was stored at -20°C. 
3.2.8.2 Isolation of total RNA 
The total RNA was extracted by Trizol Reagent (Sigma-Aldrich) according to the 
manufacturer’s protocol. Tumor tissues were homogenized in 10 volumes of Trizol reagent 
using power homogenizer, while the adherent cells were lysed directly in 6-well plates. The 
homogenized samples were incubated for 5 min at room temperature to permit a complete 
dissociation of the nucleoprotein complex. 
1ml lysates was transferred to a fresh tube, where 0.2 ml chloroform was added, vortexed 
thoroughly and incubated for 10 min at room temperature, for phase separation. 
The samples were centrifuged at 12000g and 4°C for 15 min, which led to the separation of 
the mixture into three phases (upper colorless aqueous RNA phase, middle DNA phase and 
lower red protein phase). 
Materials and Methods 
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The upper layer was carefully removed and transferred to a new tube, and 0.5 ml isopropanol 
was added and then mixed well. The mixture was allowed to stand at room temperature for 
10 min, and then centrifuged at 12000g and 4°C for 20 min.  
The supernatant was removed and the RNA pellet was washed two times with ice-cold 75% 
ethanol and then centrifuged at 7500g for 5 min at 4°C. All leftover ethanol was completely 
discarded, RNA pellets were dried (not completely) for 5 min in the heat block at 65°C, then 
dissolved in RNAase-free water and measured in a spectrophotometer to determine the 
concentration and purity of RNA. 
2 µl sample was diluted in 98 µl of DEPC-water and 50 µl of dilution was transferred to a 
spectrophotometer tube then measured. The A260/A280 should be above 1.7.  
Later some samples were measured using a Nanodrop spectrophotometer where only 2 µl 
was added directly to the machine without the need to ilute and a RNAase free-water was 
used as blank. 
3.2.8.3 Quantitative real time reverse transcription PCR 
In order to determine the expression level of microRNA and messenger RNAs, a quantitative 
real time reverse transcription PCR was performed using the light cycler detection system 
(Roche Diagnostics) and the SYBR Green PCR master mix. The expression level of 
microRNA in each cell line was measured and normalized to RNU6, which was used as 
internal control, while β-actin was used in case of transcripts normalization.  
To determine the expression level of mature microRNA, specific stem looped RT primer 
(Chen et al., 2005), while mirVanaTM specific RT primer was used for determination of 
precursor microRNA. Random hexamer primers were used for reverse transcription of 
targeted transcripts. 
Materials and Methods 
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Small RNA containing microRNA was isolated from cell lines and tumor xenografts by the 
mirVanaTM isolation Kit while total RNA was isolated using the Trizol Reagent.  
Reverse transcription was performed with 100 ng denatured RNA using recombinant 
Transcription Reverse Transcriptase as described by the manufacturer under the following 
conditions: 16°C for 30 min, 42°C for 60 min and 85°C for 5 min.  
The cDNA product  was diluted 1:10 in nuclease free water and used as a template for 
quantitative real time PCR under the following conditions: 95°C for 15 min followed by 55 
cycles of 95°C for 10 sec, 55°C for 10 sec and 72°C for 10 sec. 
Relative fold changes of microRNA and mRNAs were calcul ted by the ∆∆Ct method 
(Livak and Schmittgen, 2001) and the values were expressed as 2-∆∆Ct. 
3.2.9 Identification of the possible target mRNA for miR-143 and miR-145 
Target Scan databases such as microRNA.org, miRDB and TargetScan were all used to 
identify the predicted targets of miR-143 and miR-145. 
3.2.10 In vivo analysis of tumor growth 
For the animal experiments, athymic nude mice (6-8 weeks of age) were used and kept in 
tight cages with standard rodent chow and water available ad libitum, and a 12 h light/dark 
cycle.  
The experiments were performed according to the natio l regulations and approved by the 
local animal experiments ethical committee. Subcutaneous LS174t as well as HCT-116 
tumors were induced by inoculation of 1.5 x106 LS174t or HCT116 cells respectively in both 
flanks of the mice. At a tumor volume of ~0.5-1 cm3. One group received PEI/miRNA 
complex (miR-145 complexed with PEI F25-LMW) while another received negative control 
siRNA and a third group set as non-treated wild type control (eight mice each).  
Materials and Methods 
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The microRNA complex as well as the negative control RNA was injected intraperitoneally 
in case of LS174t xenografts or intratumorally in case of HCT-116 xenografts.  
The complexes were prepared for one injection as follows: 
1- 10 µg miR-145 or anti-Luc-siRNA as negative contr l was diluted in 100µl          
HEPES/NaCl buffer. 
2- 10 µl PEI F25-LMW (mass ratio 5) was added to 90 µl HEPES/NaCl buffer. 
3- After 5 min both tubes were mixed together (PEI solution was added to microRNA 
solution, not reverse) 
4- The complexes were incubated at room temperature for 45 min. 
5- Finally, 150 µl of complex was intraperitoneally injected. 
In case of HCT-116 xenografts, the complexes were injected intratumorally, and the amount 
of injected complex was depended on the tumor volume (50-100 µl). 
At the end of the experiment, the animals were sacrificed and tumor tissues and surrounding 
skin was excised and removed. The tumors were section d into three parts and snapped 
frozen immediately in liquid nitrogen for quantitatve real time PCR and Western Blot 
experiments, while the third section was immediately fixed in 10% paraformaldehyde for 






4.1 Reduced expression of miR-143 and -145 in different cell lines 
Quantitative real time PCR was first performed to analyze expression levels of precursor 
and mature microRNAs in 16 cell lines of different origins and compared to the non-tumor 
fibroblast cell line NIH/3T3 (Figure.4.1 A and B). Two different types of primers were 
used to determine the expression levels of precursor microRNA as well as mature 
microRNA. 
Precursor microRNAs, mir-143 and mir-145, were determined using linear specific 
primers, while mature microRNAs, miR-143 and miR-145, were analyzed using specific 
stem looped RT primers. Expression levels of Precursor and mature microRNA were 































































































































































































































































































































































































































































Figure 4.1: Relative expression level of A) precursor mir-143 and mir-145 and B) mature 
miR-143 and miR-145. All colon carcinoma cell lines showed low expression level of both 
precursor and mature miR-143 and miR-145 as compared to non-tumorous NIH3T3. 
In comparison to the normal NIH 3T3 cells, the exprssion of precursor microRNAs as well 
as mature microRNA was downregulated in all cell lines, particularly in colon carcinoma 
cells. The results also demonstrated that the expression level of precursor and mature 
microRNAs was depending on the cell line. This is particularly true for prostate carcinoma 
cells with levels being very low in DU-145 cells, while PC3 cells showed high level of 
mature miR-145. Generally, the expression level of precursor miRNAs showed low level in 
all cell lines in comparison to the correspondent mature microRNAs. For subsequent 






4.2 PEI-mediated delivery of mature microRNAs 
To validate the efficiency of Jet-PEI to deliver the microRNAs, LS174t cells were 
transfected with 50 nM mature microRNA-PEI complex. Thereafter, the levels of both 
miR-143 and miR-145 were determined through RT-qPCR method and it was found that 
the level of mature microRNAs was upregulated or, in other words, was elevated after 
transfection of exogenous mature microRNAs using Jet-PEI as transfection reagent.  
This experiment illustrated that Jet-PEI has the efficacy to complex mature microRNAs and 
to deliver them into the cells. As shown in Figure 4.2 A and B, the levels of miR-143 and 
miR-145 was markedly elevated after transfection with 50 nM miR-143 compared to non-
treated wild type cells. In the same way, the level of both miRNAs were elevated after 
transfection with 50 nM miR-145, the level of miR-143 was not as the same as the first 
assessment. 
As specific primers were designed for the detection of miRNAs, no-cross reactivity should 
have been observed. Therefore, To confirm these results, the same experiments were done 
on the RNA extract (after cell lysis), where the same concentrations of miRNAs or non-
specicfic control RNA without a transfetion reagent were added to the RNA extracts of 
LS174t cells.  
The same results (data not shown) have been observed, where the level miR-143 was 
markedly increased in case of addition mature miR-143 but not miR-145. Likewise, the 
level of miR-145 was highly elevated in case of addition of mature miR-145 but not miR-
143 (all results were compared to non-treated RNA extracts as negative control). 































   
   
   
   
   
   
   












































   
   
   
   
   
   
   






















































   
   
   
   
   
   
  
   















































   
   
   
   
   
   
  
   

























Figure 4.2: Relative level of miR-143 and miR-145 in LS174t cells after transfection with 







4.3 In vitro analysis of LS174t cells 
4.3.1 Proliferation assay 
4.3.1.1 Jet-PEI 
The functions of microRNAs in regulating cell growth and proliferation have been well 
established in recent years because they can target genes involved in cell proliferation. 
Downregulation of miR-143 and miR-145 in different types of cancer suggests their role in 
controlling cell proliferation serving as a tumor suppressor. LS174t cells as colon 
carcinoma model were transfected with different concentrations of mature microRNAs 
using different transfection reagents, Jet-PEI, INTERFERin and PEI F25-LMW. The 
different transfected concentrations were depending on the used reagent. For example, in 
case of Jet-PEI, LS174t cells were transfected with50 and 100 nM miR-143 and miR-145.          
At both concentrations, miR-145 had a profound inhibitory effect on the proliferation rate 
more than that of miR-143. As shown in the representative figures, miR-143 and miR-145 
had a marked inhibitory effect at 120 h of transfection and increased even for longer period 
until 168 h. 
Non-specific activity of PEI at both concentrations was not observed, indicated by the non-
specific control RNA, even for long period of incubation, while at 168 h (7 d), PEI-
mediated delivery of miR-145 led to a marked inhibition of proliferation (> 70% and > 55% 
after transfection with 50 nM and 100 nM, respectively). While transfection of miR-143 led 
to inhibition of growth by 40% and 2% in case of 50 nM and 100 nM respectively.  
In case of combination of both miR-143 and miR-145, each at half amounts, the 




















































































Figure 4.3.1.1: Proliferation Assay of LS174t cells after transfection with A) 50 nM and B) 






In the case of INTERFERin, LS174t cells were transfected with 20 nM and 40 nM mature 
microRNAs and in this experiment, miR-145 and miR-143 had an inhibitory effect on the 
growth rate. Consistent with the previous results, miR-145 had a greater effect than miR-
143 or even the combination between them (each half). After 168 h at 20 nM, miR-145 
reduced the growth rate by 76% while miR-143 reduce th  proliferation rate by 41%, but 
when combined of both microRNAs at half concentrations (10 nM miR-143 and 10 nM 
miR-145), a reduction by 45% was observed. All of these values were compared to the non-
specific control RNA, where non-specific activity was not detected along the incubation 
time. 
When LS174t cells were transfected with a higher concentration of microRNAs, 40 nM, 
both microRNAs had an inhibitory effect on the growth of these cells (Figure 4.3.1.2). 
More specifically, miR-145, miR-143 or the combinaton of them reduced the growth rate 
by 41%, 39% and 38%, respectively. Nevertheless, after 168 h, some of non-specific 
activity represented by the reduced proliferation of negative control RNA was observed. 
Therefore, 20 nM was used as the optimal concentration in the subsequent experiments on 


















































































Figure 4.3.1.2: Proliferation activity of LS174t cells after transfection with A) 20 nM and 





4.3.1.3 PEI F25-LMW  
LS174t cells were transfected with 5, 10 and 30 nM mature microRNAs complexed with 
PEI F25-LMW (N/P ratio 33). In these cells, miR-143 and miR-145 exerted 
antiproliferative effect that was a dose dependent. In case of transfection with 5 nM, miR-
145 inhibited the growth after 168 h by 23%, while miR-143 had no inhibitory effect and 
the non-specific activity of PEI F25-LMW has not been detected as represented by the 
negative control RNA. 
LS174t cells were further transfected by 10 nM and 30 nM and the results as shown in 
Figure 4.3.1.3 B and C, both miR-143 and miR-145 affect markedly the proliferation of 
LS174t cells in comparison to wild type cells, while the results show that there is some 
non-specific activity of PEI as indicated by negative control RNA treated cells. In case of 
transfection of LS174t cells with 30 nM mature miRNAs, both miR-143 and miR-145 
exerted antiproliferative effect as same as transfection with 10 nM, but the non-specific 



















































































































Figure 4.3.1.3: Proliferation activity of LS174t cells after transfection with A) 5 nM and B) 




4.3.2 Soft agar analysis 
The soft agar assay for colony formation is an anchorage independent assay, which is 
believed to be a reasonably good predictor of in vivo activity. The assay was done in 6-well 
plate in triplicates with manual counting by two unbiased counters. Figure 4.3.2 shows the 
efficacy of miR-145 and miR-143 to inhibit the formation of colonies after three weeks of 
incubation, when LS174t cells were transfected with 100 nM mature microRNAs or non- 
specific control RNA for 24 h before seeding in agar pl tes.  
Number and diameter of colonies were reduced in plates seeded with cells, which were 
previously transfected with mature microRNAs, in comparison to non-specific control and 
wild type cells. The number of colonies was reduced by 37% and 45% for miR-145 and 
miR-143, respectively, as compared to the negative control RNA that indicated the absence 































































Figure 4.3.2: Soft agar assay of LS174t cells transfected with 100 nM mature microRNAs. 




4.3.3 Apoptosis assay 
4.3.3.1 Increased apoptosis upon PEI-miRNA delivery  
Apoptosis is a programmed, physiological mode of cell d ath, which plays an important 
role during embryonic development, the maintenance of tissue homeostasis and the removal 
of aberrant cells. The caspases consist of a group of aspartic acid-specific cysteine 
proteases. These unique proteases, which are syntheized as zymogens, are involved in the 
initiation and execution of apoptosis once activated by proteolytic cleavage. 
Mammalian caspases may be grouped by function: cytokine activation includes caspases 1, 
4, 5, 13; apoptosis initiation includes caspases 2, 8, 9, 10; and apoptosis execution utilizes 
caspases 3, 6, 7.  
In this experiment, the LS174t cells were transfected with PEI/miRNA complex and 
apoptosis was measured after 24, 48 and 72 h using the Caspase Glo3/7 assay. While no 
change was observed at the first two time points, a light induction was detected at 72 h 
after transfection with miR-145.  
These results strongly indicated that the effectors caspases participate in the execution of 
cell death induced by miR-143 and miR-145, where apoptotic cells were increased by 20% 
to 50% for miR-143 and miR-145 respectively in comparison to wild type cells. On 
comparison to the non-specific control RNA, apoptosis has been increased by 26% and 5% 
for miR-145 and miR-143 respectively. This indicates hat both miRNAs particularly miR-

































































Figure 4.3.3.1: Activity of Caspase 3/7 in LS174t transfected with 100 nM mature miRNAs 
using Jet-PEI. 
4.3.3.2 FITC-Annexin assay 
Another assay to confirm the role of microRNAs in apoptosis has been conducted, FITC-
annexin assay. Under normal conditions, a cell maintains a strictly asymmetric distribution 
of phospholipids in the two leaflets of the cellular membranes with phosphatidylserine (PS) 
facing the cytosolic side; however, during early apoptosis this membrane asymmetry is 
rapidly lost without concomitant loss of membrane itegrity. This in turn results in the 
exposure of PS at the outer leaflet of the plasma membrane. This phenomenon can be 
detected by annexin V, which is a 35 kDa phospholipid-binding protein and has a high 
affinity for PS residues.  
At the end stage of apoptosis, where no clear distinction between classical apoptosis and 
necrosis, propidium iodide was used to detect dead cells (end stage). LS174t cells were 




activity was measured by FITC-Annexin assay using flow cytometry. It was found that It 
was found that In a FACS-based FITC-annexin assay, a > 2-fold increase in early stage and 




















































































Figure 4.3.3.2: FITC-Annexin analysis of LS174t cells transfected with 100 nM mature 





4.3.4 Relative expression level of ERK5 
 ERK5 is a member of mitogen activated protein kinase nd it was reported as a direct 
target for miR-143 but not miR-145 (according to surveyed databases). 
In this experiment, a quantitative analysis of ERK5 transcripts was measured by Real time 
PCR after transfection of LS174t cells with 100 nM mature microRNAs using jet-PEI and 
20 nM using INTERFERin as transfection reagents.  
LS174t cells were transfected with mature microRNAs or non-specific control RNA and 
incubated for 5 d, and then total RNA was extracted as escribed in chapter 2. Figure 4.3.4 
shows that neither miR-145 nor miR-143 has an inhibtory effect on expression level of 
ERK5 transcripts. 
Nevertheless, at the posttranscriptional level, miR-143 and mir-145 decreased the level of 
ERK5 in dose dependent manner, where at concentration 50 nM, miR-143 and miR-145 
decreased the total ERK5 pool by 44% and 25.5%, respectively, while at concentration    
100 nM the rate of reduction was 67.8% and 46.5% for miR-143 and miR-145, 
respectively. These results were compared to non-specific control RNA, which showed 
absence of non-specific activity at 50 nM as well as at 100 nM either at the transcriptional 
























































































































Figure 4.3.4: Relative expression levels of ERK5 in LS174t normalized to actin. The upper 
right graph shows the expression level of ERK5 mRNA in LS17t cells transfected with 100 
nM miRNAs complexed with Jet-PEI and the upper leftgraph shows 20 nM miRNAs 
complexed with INTERFERin. The lower Panel shows the expression level of ERK5 
proteins in LS174t cells transfected with 50 nM mature miRNAs (right) and 100 nM 





4.3.5 Relative expression level of c-Myc  
  The correlation between microRNAs and c-Myc was further examined by 
evaluating the expression of c-Myc in human colorectal arcinoma LS174t cells after 
transfection of miR-143 and miR-145. LS174t cells were transfected with 100 nM mature 
microRNAs/Jet-PEI complex or 20 nM miRNA complexed with INTERFERin in 
comparison to control cells transfected with non-specific control RNA and wild type cells 
(not transfected).  
As shown in Figure 4.3.5, when the cells were transfected with 100 nM mature miRNA, the 
expression of c-Myc transcripts were reduced by 33% and 17% after transfection with miR-
145 and mir-143 respectively. In contrast, in cells transfected with mature microRNA 
complexed with INTERFERin, no significant change of the expression level was detected.  
The level of c-Myc protein was messured using the Western Blot analysis after transfection 
of LS174t cells with 100 nM miRNAs/Jet-PEI complex. The results showed that miR-145, 
to some extent, decreased the expression level by 7%. All results were compared to non-
specific control RNA, which showed the absence of the non-specific activity during the 
































































































Figure 4.3.5: Relative expression level of c-Myc in LS174t normalized to actin. A) 100 nM 
with Jet-PEI and B) 20 nM with INTERFERin. The upper Panel shows the expr ssion level 
of c-Myc mRNA in LS17t cells transfected with 20 nM miRNAs complexed with 
INTERFERin and 100nM miRNAs complexed with JET-PEI. The lower Panel shows the 
expression level of c-Myc proteins in LS174t cells transfected with 100 nM miRNAs 






4.3.6 Anti-tumor effects of intraperitoneal PEI-mediated miR-145 
delivery in s.c LS174t colon carcinoma xenograft mouse model 
The purpose of the in vivo studies was to study the effect of miR-145 on the growth of solid 
tumors. To achieve this, athymic nude mice were injcted subcutaneously with 1.5*106 
LS174t cells in both flanks of the mice. 
After the development of solid tumors, the mice were g ouped into three groups (eight mice 
each), the mice were treated with miR-145/PEI complex or the non-specific control treated 
group or left untreated. The tumor volume was measured every 48 h using the formula 
(width * length * height) where, the length was the larger value, and at the same interval, 
the mice were injected intraperitoneally with 10 ug microRNA or non-specific control 
RNA. 
A difference between the tumor volume in the microRNA treated group and the other 
groups was recognized after 10 d of treatment; i.e. aft r five injections. After about 23 d, a 
significant difference in the tumor growth between different groups was detected as shown 
in Figure 4.3.6. These results indicated that the PEI/miR-145 had the efficacy to inhibit the 
growth of the solid tumors through either an indirect ffect or by direct acting on cancer 
related genes. 
As illustrated in Figure 4.3.6, a non-specific activity of PEI was not observed as 
represented by the activity of the non-specific control RNA when compared to the wild 






Figure 4.3.6: Anti-tumor effects of PEI/miR-145 treatment in s.c. LS174T colon carcinoma 
xenograft mouse models. (a) Systemic injection of PEI/miR-145 complexes results in 
reduced tumor growth (red) as compared to untreated (black) or PEI/RNA negative control 
treated mice (green) 
4.3.6.1 Expression level of miR-145 targets in s.c LS174t xenografts 
To evaluate the biological effect of miR-145 on colon carcinoma tumorgenesis, molecular 
and biochemical analyses on tumors after sacrificing the mice were performed. 
The tumors were sectioned into three parts, frozen in liquid nitrogen and kept in -80oC, one 
part for quantitative analysis of target mRNAs, thesecond part for Western blot assay, 
while the third part was preserved in 10% paraformaldehyde for immunohistochemistry 
preparation. 
To validate the efficiency of PEI mediated delivery of miR-145 in vivo, tumor sections 
from miR-145 treated mice, negative control group and the wild type untreated group were 




small-enriched RNA (including the microRNAs fractions). As expected, a high level of 
miR-145 in treated samples (Figure 4.3.6.1A) has been observed in comparison to wild 


























































Figure 4.3.6.1A: miR-145 expression level in s.c LS174t colon carcinoma xenograft 
models. 
Based on the in vitro data, ERK5 and c-Myc were the selected targets for both miR-143 and 
miR-145. To evaluate the silencing effect of mature miR-145 on these targets at the level of 
transcripts, a quantitative real time PCR was done.  
Quantitative real time PCR assay in vivo indicated that ERK5 transcripts were non-
significantly downregulated by miR-145 compared to the non-specific control RNA. The 
same results were obtained for the oncogen c-myc, a possible target for miR-145, where no 
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Figure 4.3.6.1 B: Quantitative real time PCR of ERK5 (upper graph), c-Myc (lower panel) 







4.3.6.2 Expression of ERK5 and c-Myc at the post-transcriptional level 
To determine the post-transcriptional effect of PEI/miR-145, the tumor sections were lysed 
and the protein was extracted and measured as described in chapter 2.  
The expression level of ERK5 and c-Myc was measured by using specific antibodies. As 
shown in Figure 4.3.6.2, an inhibitory effect of mature microRNA on the expression level 
of both ERK5 and c-Myc was detected. The level of ERK5 was downregulated by 48% in 
miR-145 treated group in comparison to the non-specific control RNA. In case of c-Myc, 



















































































































































































Figure 4.3.6.2: Western blot analyses of ERK5 (upper annel) and c-Myc (lower pannel) in 
s.c LS174t colon carcinoma xenografts. 
4.3.6.3 Reduced expression level of PCNA 
The tumor sections were stained for evaluation of PCNA expression levels. The results of 
PCNA staining were analyzed according to the intensi y of the stained nuclei, wit the value 
0 denoting no staining, 1 poor staining, 2 moderate staining and 3 intensive staining. As 
illustrated in Figure 4.3.6.3, it was found that the intraperitoneal injection of miR-145 led to 




nuclei of PCNA in comparison to the negative control or the untreated wild type. The 
expression level of PCNA was reduced by 48% in comparison to the negative control RNA. 
Until now, PCNA was not reported as a direct target for miR-145, despite this fact, a slight 
effect of miR-145 on the expression level of PCNA transcripts has been detected. However, 
this effect could be due to an indirect effect of miR-145. 
The comparison between non-transfected and negative control transfected cells also 
demonstrated the absence of non-specific PEI effects on the expression level of PCNA.  












































































































Figure 4.3.6.3 Expression level of PCNA in s.c LS174t xenografts. The upper panel shows 






4.4 HCT-116 cells 
4.4.1 Proliferation assay- Jet-PEI 
HCT-116 cells were transfected with different concentrations of mature microRNAs or 
negative control RNA using Jet-PEI and INTERFERin as tr nsfection reagents. 
No inhibitory effect of both miR-143 and miR-145 was detected when HCT-116 cells were 
transfected with 50 nM using jet-PEI as a transfection reagent. Yet, when the cells were 
transfected with 100 nM, slight changes were observed, since miR-145 and miR-143 
reduced the proliferation rate by 17% and 10%, respectively, compared to the negative 
control RNA. 
Non- specific activity of PEI was not observed in all used concentrations, which indicated 












































































Figure 4.4.1: Proliferation of HCT-116 cells upon transfection with 50 nM and 100 nM 
miR-143, miR-145 or negative control RNA. 
4.4.2 Proliferation assay- INTERFERin 
INTERFERin was used as a transfection reagent to transfect HCT-116 cells with different 
concentrations of mature microRNAs, 5 nM, 10 nM and20 nM. As shown in Figure 4.4.2, 
a profound inhibitory effect of miR-145 and miR-143 on the proliferation rate was 
observed after 120 h. 
When the cells were transfected with 5 nM miRNAs or negative control, a marked 
inhibitory effect of both miR-145 and miR-143 was detected, where miR-145 and miR-143 
reduced the cell proliferation by 35% and 28%, respectively, compared to the non- specific 
control RNA.  
Increasing the concentration of microRNAs to 10 nM led to a reduction of the proliferation 




control, while non-specific toxicity of INTERFERin has not been observed, but in case of 
transfection with 20 nM, a further reduction of the proliferation rate was detected by 41% 












































































































   
Figure 4.4.2: Proliferation activity of HCT-116 after transfection with 5 nM, 10 nM and 20 
nM of miR-143, miR-145 or negative control RNA complexed with INTERFERin. 
4.4.3 Soft agar assay of HCT-116 cells 
HCT-116 cells were transfected with 20 nM miR-143, miR-145 or the non-specific control 
RNA complexed with INTERFERin. The cells were seeded onto agar plates and incubated 
for 21 days. Two unbiased investigators counted the formed colonies and it was shown that 
miR-143 and miR-145 reduced the proliferation rate, number and size, by 44% and 43% 
respectively. 
As illustrated in Figure 4.4.3 and the representing images, the comparison between the 
negative control RNA transfected cells and wild type untreated cells showed the absence of 
non-specific activity of INTERFERin, which is consistent with the previous results at the 




































































Figure 4.4.3: Anchorage independent assay of HCT-116 cells transfected with 20 nM 
miRNAs complexes formed with INTERFERin. 
4.4.4 Relative expression levels of ERK5 and c-myc in HCT-116 cells 
The expression levels of ERK5 and c-Myc were determined in HCT-116 cells transfected 
with 20 nM miRNAs complexed with INTERFERin as transfection reagent. At the 
transcriptional level, ERK5 was downregulated by 43% and 34% when the cells were 
transfected with miR-143 and miR-145, respectively, compared to the non-specific control 
RNA, which showed absence of a non-specific effect. 
Likewise, at the post-transcriptional level, a downregulation of ERK5 protein was detected, 
where both miR-143 and mir-145 reduced the expression level by 41% and 23% for miR-




The proto-oncogene c-myc was also evaluated as an important tumorgenic target for both 
miR-143 and miR-145. At the transcriptional level, c-myc transcripts were slightly 
downregulated by 3% and 10% for miR-143 and miR-145, respectively, compared to the 
negative control, which showed absence of non-specific effect on the expression level. 
At the post-transcriptional level, c-Myc protein was downregulated by 44% and 15% for 


































































































































































































Figure 4.4.4: Relative expression of ERK5 (upper panel), c-Myc (lower panel) at the 
transcriptional and post-transcriptional level in HCT-116 cells transfected with 20 nM 
microRNAs using INTERFERin. 
4.4.5 Anti-tumor effect of intratumorally PEI-mediated delivery of miR-
145 in s.c HCT-116 colon carcinoma xenograft mouse model 
To further explore the therapeutic applicability ofPEI/miR-145 complexes, a local 
treatment regimen was tested next. In these experiments, the particularly tumorigenic colon 
carcinoma cell line HCT-116 was selected. Again, the mice were grouped into three groups, 
eight mice each. One group was treated by intratumoral injection of PEI-complexed miR-
145, the second group was injected with the PEI-complexed non-specific control RNA and 




week and was started after the establishment of tumor xenografts; however, since PEI 
complexes were applied locally, amounts were depending on the tumor size (50-100 ul). 
 Untreated tumors showed a rapid growth with a ~ 8-fold increase over 2.5 weeks (Figure 
4.4.5). Reduced tumor growth was observed in the PEI/negative control RNA group, 
indicating some non-specific effects of the PEI complexes upon local injection. Notably, 
the intratumoral application of PEI-complexed miR-145 resulted in a very profound tumor 
growth inhibition, with tumor volumes in the treatment group being ~40% or ~60% of the 
untreated or negative control treated tumors, respectively. Based on the previous results, a 
therapeutic potential of PEI/miR-145 to reduce the tumor growth in vivo by targeting some 






























































Figure 4.4.5: Tumor-inhibitory effects of PEI/miR-145 complexes in s.c. HCT-116 colon 
carcinoma xenografts upon intratumoral injection. The local administration leads to some 
non-specific effects of PEI/negative control RNA complexes (green) as compared to 
untreated controls (black); more profound effects, however, are observed in the PEI/miR-




4.4.5.1 Expression levels of ERK5 and c-myc in s.c HCT-116 xenografts 
HCT-116 xenografts were exposed to quantitative real time PCR analysis, where the 
expression levels of ERK5, c-myc mRNA level were determined. As shown in Figure 
4.4.5.1, it was found that the expression level of these targets was not significantly changed 
in comparison to the non-specific control RNA xenografts. In case of ERK5, the expression 
of transcripts was downregulated by 30% compared to the non-specific control RNA, 
which indicated also the absence of the non-specific activity of PEI. 
At the protein level, no significant reduction was observed. While the expression level was 
downregulated by 29% in PEI/miRNA complex treated xenografts compared to the non-
specific control RNA, large standard deviations prevented more solid conclusions. 
In case of c-myc, no effect of PEI/miR-145 was detected at neither the transcriptional level 
nor post-transcriptional level. Based on the previous results, a general conclusion has been 
established that the therapeutic effect of PEI-miR-145 complex is depending on the 

































































































































































































































Figure 4.4.5.1: Relative expression level of ERK5 (upper graph), c-Myc (lower graph) in 
s.c HCT-116 colon carcinoma mouse xenografts. 
4.4.5.2 Expression levels of PCNA in s.c HCT-116 xenografts 
Immunohistochemistry assay was conducted to examine the xpression status of PCNA in 
the HCT-116 induced xenografts. The evaluation of PCNA staining was semi-quantitative, 




value 0 to 3 (0 for no staining, 1 for poor staining, 2 for moderate staining and 3 for strong 
staining). The slides were evaluated by unbiased counters. 
Intensity of PCNA staining was reduced by 49% in tumors, which had been treated with 
PEI/miR-145, compared to the negative control RNA. This result is almost consistent with 
data found in LS174t-induced tumors, which indicates the antiproliferative role of miR-145 
in colon cancer.  
At the transcriptional level, PCNA was downregulated by 18% in miR-145 treated tumors 


















































































































Figure 4.4.5.2 Expression levels of PCNA in s.c HCT-116 induced xenografts. The upper 
panel shows the PCNA transcript levels. The lower panel shows immunohistochemistry 





The general feature of cancer is the loss of cell identity and aberrant proliferation. 
Characteristically, oncogenesis is the accumulation of mutations in protein encoding genes 
or tumor suppressors (McManus, 2003). A new class of non-protein coding, endogenous, 
small RNAs has been discovered ,these molecules were named microRNAs, and were 
found to be important regulatory molecules in animals and plants (Zhang et al., 2007). 
MicroRNAs are important post-transcriptional regulators of gene expression that control 
diverse physiological and pathological process. This regulation allows for fine tuning of 
cellular processes, including regulation of proliferation, differentiation and apoptosis 
(Winter et al., 2009). MicroRNAs and their targets seem to form complex regulatory 
networks. For examples, a single microRNA can bind to and regulate many different 
messenger RNA targets and, conversely, several different miRNAs can bind to and 
cooperativey control a single mRNA target (Lewis et al., 2003). It was reported that more 
than one third of all human genes are regulated by miRNAs (Lewis et al., 2005). 
Since the discovery of a functional RNA interferenc (RNAi) strategy in mammals, 
significant efforts have been undertaken to develop therapeutics that utilize this pathway 
(de Fougerolles et al., 2007). While progress has been made toward the design and delivery 
of short interfering and short hairpin RNAs for therapeutic gene silencing, accumulating 
evidence indicates that the modulation of miRNA activity also represents an attractive 
strategy (Baek et al., 2008; Selbach et al., 2008). 
The therapeutic application of miRNAs involves two strategies. One strategy is directed 
against a gain of function and aims to inhibit oncogenic miRNAs, whereas the second 
strategy, microRNA replacement, involves the reintroduction of a tumor suppressor 
miRNA to restore a loss of function (Johnson et al., 2007; Esquela-Kerscher t al., 2008; 




Many strategies of siRNA delivery have been developd from viruses as natural vehicles to 
liposomes, nanoparticles or bacteria (transkingdom RNAi) (Li, 2006; Aigner, 2009; Kruhn 
et al., 2009; Nguyen and Fruehauf, 2009). 
In this work, for the first time, one of the most widely examined synthetic cationic 
polymers, polyethylenimine, was used for microRNA delivery in vitro and in vivo. 
Two types of polyethylenimine were used, linear Jet-PEI and branched low molecular 
weight, 4-10 kDa PEI, which was prepared from commercially available 25 kDa PEI. 
Variations in their transfection efficiency as well as their cytotoxicity were found, which 
were depending on the used N/P ratio, the type of transfected cell lines and the period of 
transfection time.  
The expression levels of both precursor and mature miR-143 and miR-145 were determined 
by quantitative real time PCR in 16 different cell lines representing different types of 
cancers such as colon cancer, prostate, bone marrow, ovary, lung, skin.  
The quantification of the mature miRNAs by PCR presented a challenge because of the 
critical size, 19-22 nt, to be detected by standard PCR primers. For this reason, a new real-
time PCR assay to quantify the mature miRNA was employed, stem-loop RT-PCR (Chen t 
al., 2005).  
One of the benefits of the analysis of microRNA expr ssion is to use them in prognosis of 
cancer in the first stages as biomarkers and/or use them to monitor the responsiveness to the 
clinical treatment (Akao et al., 2006; Osaki et al., 2008). 
Both miR-143 and miR-145 were found to be downregulated in all colon carcinoma cell 
lines. In agreement with these results, these microRNAs were significantly downregulated 
in colorectal carcinoma (Michael t al., 2003; Akao et al., 2006; Slaby et al., 2007; Takagi 
et al., 2009), in prostate cancer (Porkka et al., 2007; Ozen et al., 2008), in bladder cancer 




The expression level of precursor microRNAs was far mo e downregulated than that of the 
corresponding mature; this may be due to the fast turnover of precursor microRNAs 
compared to mature microRNAs. In another study carried out by Michael and colleagues, 
they found that precursor microRNAs were accumulated in both normal and cancerous 
tissue and they attributed this result to reduced activity of the components of the microRNA 
processing machinery such as Dicer proteins (Michael et al., 2003). 
Reduced expression levels of these microRNAs can be attributed to the presence of the 
microRNA genes in fragile sites exposed to mutations, and in fact, it was previously found 
that p53 response elements, responsible for the activation of transcription, lie in the 
promoter region of the miR-145 gene. p53 is known to be inactivated in several cancers 
which in turn may inactivate transcription of miR-145 (Sachdeva et al., 2009). Another 
reason which could explain the reduction of the expr ssion level of microRNAs is the DNA 
hypermethylation (Ostenfeld et al., 2010). 
In order to evaluate the therapeutic abilities of microRNAs, two colon carcinoma cell lines, 
LS174t and HCT-116, were selected.  
In this work, it was demonstrated that linear Jet-PEI has the ability to complex and to 
deliver microRNAs efficiently (when after transfecting the LS174t cells with miRNAs/Jet-
PEI and incubated for 48 h, the levels of microRNAs were analyzed by quantitative real 
time PCR). Interestingly however, it was found that when the LS174t cells were transfected 
with miR-143 or miR-145, the level of both microRNAs, the transfected miRNA and the 
non-transfected miRNA, were elevated. These results could account for a mutual 
relationship between transcription of both miR-143 and miR-145.  
Previously, it was reported that miR-143 and miR-145, which are localized at 5q32, are 
possibly transcribed as the same primary microRNA (pri-miRNA) (Takagi et al., 2009). To 
confirm absence of cross reactivity of primers, miR-143 or miR-145 was added directly to 
the vials of RNA extracts. It was found that the level of miR-143 or miR-145 was 




observed but not miR-145. Moreover, when miR-145 was added, the level of miR-145 was 
high but not miR-143. This indicates the specificity of both primers and no-cross reactivity 
was detected. 
This establishes the efficiency of Jet-PEI to deliver microRNAs into the cells. Consistently, 
the efficient transfection of mature miR-145 in vitro was confirmed after 12, 24 and 48 h by 
transfection with Lipofecatmine as a delivery reagent (Ostenfeld et al., 2010). 
Upon transfection of LS174t with PEI/miR-143 or PEI/miR-145, the rate of proliferation 
was markedly reduced. In case of Jet-PEI complexed with 50 nM or 100 nM mature 
microRNAs, the proliferation rate was reduced over a long time, 120h. Earlier studies have 
shown the ability of miR-145 to reduce the growth rate in colon and cervical cancer cells 96 
h post transfection (Shi et al., 2007; Schepeler et al., 2008; Wang et al., 2008). 
Previously, it was found that both microRNAs reduced the proliferation of human gastric 
cancer  MKN-1 cells by 55-60% in comparison with contr l cells (Takagi et al., 2009). 
Furthermore, the function of both miRNAs in cell growth was evaluated, when two colon 
carcinoma DLD-1 and SW480 cells were transfected with 20-80 nM precursor miRNAs 
(Akao et al., 2006, , 2007b). By transfection of three different colon carcinoma cell lines 
DLD-1, LS174t and HCT-116 with miR-145, the growth rate was markedly reduced 
(Schepeler et al., 2008). 
However, in case of transfection of HCT-116 cells using Jet-PEI, only little effects of both 
microRNAs were detected. The HCT-116 cells were transfected with 50 nM and 100 nM 
miR-143, miR-145 or negative control RNA. This could be due to the cell type and its 
cytogenetic profile. 
Upon transfection of LS174t cells with INTERFERin at concentrations 20 nM or 40 nM 
mature miRNAs, a profound inhibitory effect of miR-145 was already observed at 20 nM. 




inhibitory effect of miR-143, miR-145, or of the combination of both increased, however a 
slight toxic effect of the negative control was detected in comparison to the wild type cells. 
Upon transfection of HCT-116 cells with three different concentrations of mature 
microRNAs (5 nM, 10 nM and 20 nM) complexed with INTERFERin, the proliferation rate 
was fluctuating depending on the concentration and number of seeded cells. In these 
experiments, several parameters had to be optimized to set reliable results. Among others 
these included the number of seeded cells, which was found to be optimal at 200-300 cells 
per well. 
Transfection of LS174t cells with different concentrations of microRNAs ranging from      
5 nM to 30 nM using another type of transfection reagent, branched PEI F25-LMW, also 
led to an inhibition of growth. The proliferation was effectively reduced upon transfection 
with miR-145 and miR-143. A toxicity or non-specifi activity of PEI was detected at       
30 nM.  
Compared to branched low molecular weight polyethylenimine, linear PEI had high 
transfection efficiency in vitro studies. This may be attributed to the large size of 
polyplexes containing linear-PEI in salt containing buffer compared to those prepared with 
its branched form  (Wightman et al., 2001; Kunath et al., 2003). Larger particles sediment 
onto seeded cells more quickly than smaller ones, which may result in an increase of 
particle uptake in vitro (Boussif et al., 1996; Ogris et al., 1998). Furthermore, it has been 
postulated that large particles show a higher intrinsic endolysosomal activity, which may 
enhance their escape from the acidic compartment (Ogris et al., 1998). 
The anti-proliferative activity of miR-145 was more profound than that of miR-143 after 
transfection with the three previously mentioned concentrations. The anti-proliferative 
results confirmed that the inhibitory effect of microRNAs is depending on the cell line, the 




Some genes associated with proliferation and oncogenic activities had been previously 
found to be targeted by miR-145. These genes are responsible for cellular transformation 
such as insulin Receptor Substrate-1 (IRS-1) (Ostenfeld et al., 2010), and YES and STAT1 
in colon cancer cells DLD1 and HCT-116 (Gregersen et al., 2010). 
This thesis could also demonstrate that PEI F25-LMW mediated miR-145 delivery in vivo. 
Consequently, s.c tumor growth was reduced. The in vivo studies were conducted by 
injection of athymic nude mice subcutaneously with cell lines LS174t or HCT-116. In the 
in vivo experiments, the PEI F25-LMW/miR-145 complex was introduced intraperitoneally 
in case of LS174t tumors or intratumorally in case of HCT-116 tumors in comparison to     
a non-specific LUC3 siRNA negative control and the wild type untreated groups. 
Both experiments showed a profound suppressor effect of miR-145 on the growth of 
tumors, which indicated the promising therapeutic ability of microRNAs in regulating 
and/or suppressing of tumors either as single therapeutic agents or in synergistic 
combination with other strategies. 
Compared to the intratumoral application of PEI-complexed miR-145, it was found that the 
intraperitoneal injection was more efficient. Over 25 d, a non-specific activity was not 
observed in case of intraperitoneally-injected PEI/miR-145 complex as indicated by the 
negative control RNA treated tumors. In contrast, in ratumoral injection of PEI/miR-145 
showed some non-specific activity at the 18th day. 
Soft agar assay set a standard method to validate the ffects expected in the in vivo colon 
carcinoma models. The transfection of miR-143 and miR-145 affected tumor cell growth, 
number and size, as indicated by anchorage-independnt growth of colon cancer cells 
LS174t and HCT-116 in the soft agar layer. These results provided strong evidence that 
miR-143 and miR-145 have a role in suppressing tumor gr wth. In LS174t cells and HCT-
116 cells, the miR-143 and miR-145 showed a profound inhibitory effect on colony 




The introduction of miR-143 had been shown previously to affect not only the proliferation 
rate but also the growth rate and colony formation of colon cancer cell lines 228 and 
SW480 in soft agar plates (Ng et al., 2009). Based on the results of this thesis, however, in 
combination with the proliferative assays, miR-145 as promising candidate was chosen to 
proceed with in vivo studies.  
It was found that there is a relation between expression levels of microRNA and the fate of 
the cancer cells. For this reason, apoptosis assay on LS174t cells after transfection with 100 
nM miRNAs were performed. Two different types of apoptosis assays, caspase Glo 3/7 
assay and FITC-annexin assay were performed. In the first assay, miR-145 and miR-143 
induced high levels of caspase 3/7 in comparison to the negative control RNA treated cells. 
After normalizing the results to the wild type (untreated cells), apoptosis levels were higher 
in negative control cells as compared to the wild type untransfected cells, which may reflect 
a non-specific transfection effect. Still, apoptosis was further increased upon transfection 
with miR-145 or miR-143. Previously, it was also proved that miR-145 is involved in 
caspase-dependent and independent apoptosis in bladder tumors and inhibits colon cancer 
proliferation (Shi et al., 2007). 
At the beginning of apoptosis, the early phase, the p ospholipid phosphatidylserin (PS) is 
translocated to the outer surface of plasma membrane, which can effectively bind to and be 
detected with annexin. During the end stage of apoptosis, the cells lose their membrane 
integrity and there is no sharp distinction between apoptotic cells or necrotic cells. In this 
case, another dye, propidium iodide, was used. This dye detects only the dead cells but not 
viable ones. So by using double staining, FITC annexin-propidium iodide, a differentiation 
between the early and the end phase can be made. 
Apoptosis of LS74t was induced after transfection with miR-143 and miR-145, where miR-
145 induced both early and end phase of apoptosis higher than that of miR-143. This 
indicates the involvement of microRNAs in the initiation of apoptosis either directly or in 
combination with other molecular effectors. ERK5 is a pro-survival kinase during mitosis 




initiated. Therefore, all of these data would tell us that there is a relationship between the 
expression level of microRNAs, levels of ERK5 and the apoptosis process. 
It was found previously that miR-143 induced the Fas-dependent apoptosis by targeting the 
ERK5 which leads to caspase activation (Akao et al., 2009). Some genes were found to be 
involved in the apoptosis network and at the same ti argeted by miR-145.  
Zhang and coworkers reported that miR-145 targets the DNA fragmentation factor-45 
(DFF45) protein, the caspase-3 and caspase-7 substrate, (Zhang et al., 2010). This protein 
forms a heterodimer with another protein DFF40, a protein responsible for generation of 
double-stranded breaks in inter nucleosomal chromatin regions as well as the chromatin 
condensation of the DNA during the apoptosis. DFF45 must be cleaved  to release the 
DFF40 before the DNA fragmentation process (Widlak et al., 2000).  
ERK5 may be a direct or indirect target of miR-143 (Esau et al., 2004), while (Clape et al., 
2009) showed that ERK5 is a direct target of miR-143 in prostate cancer, as evidenced by 
the presence of a seed sequence of miR-143 in the 3’UTR of ERK5 mRNA. This fact was 
also reported by (Akao et al., 2007a), who reported that the microRNAs miR-143 and miR-
145 were downregulated in chronic lymphocytic leukemia and that ERK5 is a direct target 
of miR-143. For the first time, this work reports tha  ERK5 was also influenced by miR-
145, directly or indirectly. 
Over-expression and activation of mitogen activated protein kinase receptors has been 
detected in colorectal cancer and has an important ole in colorectal cancer progression 
(Fang and Richardson, 2005). Furthermore, ERK5 has been shown to be involved and to 
have a potential role in breast cancer initiation and progression (Montero et al., 2009). In 
vivo studies using animals in which ERK5 expression can be regulated, have demonstrated 
that ERK5 is important for sustaining tumor growth, probably due to its supportive role in 




In this work, the level of ERK5 (transcript and protein) was determined in lysates of 
LS174t cells and HCT-116 cells, which were transfected with different concentrations of 
mature microRNAs using Jet-PEI or INTERFERin as transfection reagents. Upon 
transfection of the LS174t cells with 100 nM miRNAs/Jet-PEI complex or with 20 nM 
miRNAs/INTERFERin complex, no significant change of ERK5 at the transcriptional level 
was observed.  
HCT-116 cells were transfected with only 20 nM miRNAs/INTERFERin complex 
(depending on the proliferation results). ERK5 exprssion at both transcriptional and 
posttranscriptional level was downregulated in HCT-116 cell lysate after transfection with 
miR-143 or miR-145. 
The expression level of ERK5 at the post-transcriptional level was evaluated. After 
transfection of LS174t cells with 50 nM and 100 nM miRNA complexed with Jet-PEI, the 
expression of ERK5 was markedly downregulated in a dose-dependent manner. At both 
concentrations, miR-143 had the higher activity than that of miR-145 in comparison to the 
negative control RNA. Nevertheless, miR-145 had a downregulatory effect on ERK5. 
Moreover, ERK5 protein was downregulated after transfection with 20 nM miRNAs 
complexed with INTERFERin. 
It has been found previously that the proto-oncogene c-myc plays an important role in 
gastric carcinogenesis and it is estimated to be involved in 20% of all human cancers 
(Dang, 1999). However, c-myc expression was also evaluated at transcriptional and 
posttranscriptional level in both LS174t cells and HCT-116 cells. 
In LS174t cells, the levels of c-myc transcripts was downregulated after transfection with 
100 nM miRNAs/Jet-PEI complex, but no change in case of INTERFERin was detected. In 
contrast, the levels of c-Myc protein was not signif cantly downregulated in LS174t cells in 
case of transfection with miR-145, and no change at all was observed in case of miR-143. 
In HCT-116 cells, the levels of c-myc transcripts was not changed. Nevertheless, at the 




Comparing the results, which emerged from the analysis of either transcript levels or 
protein levels, the microRNAs exerted a post-transcriptional regulatory role in the cells. 
Moreover, the results indicate that the expression level of targets, ERK5 or c-myc depends 
on the intracellular level of microRNAs, cell line or the transfection reagent. By this 
mechanism, microRNAs regulate about 30% of human genom  (Lewis et al., 2005). 
Furthermore, the expression of ERK5, c-myc and PCNA in the s.c tumors at both 
transcriptional and post-transcriptional level were valuated. In LS174t-induced xenografts, 
the expression level of ERK5 and c-myc transcripts were not changed, while levels of 
PCNA were downregulated in miR-145/PEI treated mice in comparison to the negative 
control RNA tumors.  
At the protein level, c-Myc and ERK5 were downregulated in LS174t-induced xenografts 
in comparison to the negative control, which indicates that miR-145 interferring the 
translation of these targets at translational level. As it was before indicated that, c-Myc is a 
direct target of miR-145 but ERK5 has not proved as a direct target yet. Nevertheless, 
ERK5 is downregulated by miR-145 and this may be duto an either direct or indirect 
effect.  
In HCT-116-induced xenografts, ERK5 and PCNA transcripts were downregulated in miR-
145 treated tumors in comparison to the negative control, while no change was not 













Figure 5: Schematic representation showing effects of miR-145 and miR-143 on the 
proliferation and survival of cancer cells. 
 
The expression level of PCNA in both LS174t and HCT-116 xenografts was demonstrated 
by immunohistochemistry using a mouse monoclonal anti-PCNA antibody. The 
proliferating cell nuclear antigen is an essential regulator of the cell cycle, which is highly 
conserved between species (Bravo, 1987). The results howed a decrease in the intensity of 
stained nuclei. This result was in accordance with the tumor growth profile, which 
indicated the efficiency of using the PCNA as a reliable biomarker of the proliferation 
process. Moreover, this finding establishes in vivo the anti-proliferative effect of PEI-





MicroRNAs (miRNAs) are small RNA molecules with perfect or imperfect homology to 
their target mRNA. They have been shown to specifically interfere with the expression of 
their target protein(s). Moreover, microRNAs play an important role in the pathogenesis of 
cancer, where some microRNAs act as tumor suppressors by targeting lethal oncogenes, 
and others act as oncogenes by targeting suppressor genes. Thus, microRNAs can be 
involved directly or indirectly in important cellular processes such as proliferation, 
differentiation and apoptosis. Understanding the functions and importance of microRNAs 
could lead to the discovery of new strategies for controlling of cancer. 
This thesis was aiming at the possibility of using on-viral delivery systems for 
microRNAs into mammalian cell lines, and examined their efficacies. To this end, three 
different transfection reagents, linear Jet-PEI, branched PEI F25-LMW and INTERFERin, 
were used in vitro, either commercially available or prepared in our lab. The work was 
concentrating on colon cancer as a tumor model, and two representative cell lines, LS174t 
and HCT-116, were selected as a platform to conduct the experiments. The studies focused 
on miR-143 and miR-145, which had been implicated previously with cancer development 
and progression.  
It was found in miRNA transfection experiments that miR-143 and miR-145, which are 
downregulated in colon cancer, have the ability to inhibit the progression of the cancer 
through different regulatory mechanisms, proliferation and apoptosis.  
Some important genes, which play important roles in tumorigenesis and tumor progression, 
were found to be negatively regulated by both miR-143 and miR-145. More specifically, 
ERK5 (Mitogen Activated Protein Kinase) which plays an essential role in the proliferation 
of colon cancer was suppressed by miR-143 and miR-145. Likewise, c-Myc was negatively 
regulated by miR-145, but these results were only at the protein level, i.e., no significant 




inhibitory effects were depending on several factors such as cell line, transfection reagent, 
time of incubation and concentration of miRNA complex.  
Thus, the cellular delivery of microRNAs miR-143 and miR-145 showed profound 
inhibitory effects on the proliferation and soft agar colony formation of LS174t and HCT-
116 cells, and induced apoptosis in LS174t cells.  
Moreover, miR-145 was examined for its tumor inhibitory effect in vivo. To this end, 
athymic nude mice bearing s.c. colon carcinoma xenografts were treated with PEI-
complexed miR-145 by systemic or local injection. Profound anti-tumor effects upon PEI-
mediated miR-145 delivery were found which were again dependent on the downregulation 
of specific target genes.  
Taken together, microRNA replacement therapy may represent a promising approach in 
tumor treatment, and this thesis establishes the PEI-mediated therapeutic delivery of miR-










MicroRNAs (miRNAs) sind kleine RNA-Moleküle mit vollständiger oder unvollständiger 
Homologie zu ihrer Ziel-mRNA. Damit sind sie in der Lage, spezifisch die Expression 
einzelner Proteine zu beeinflussen. MicroRNAs spielen eine wichtige Rolle in der Krebs-
Pathogenese, indem einige miRNAs gegen Onkogene gerichtet sind und somit als Tumor-
Suppressoren fungieren, während andere miRNAs Onkogene darstellen und gegen Tumor-
Suppressoren gerichtet sind. MiRNAs können somit direkt oder indirekt an wichtigen 
zellulären Prozessen wie Proliferation, Differenzierung und Apoptose beteiligt sein. Das 
Verständnis ihrer Funktionen und ihrer Relevanz könnte zur Entwicklung neuer Strategien 
in der Kontrolle von Tumoren führen.  
Diese Arbeit untersuchte die Möglichkeit und Effizienz nicht-viraler 
Einschleusungssysteme für miRNAs in Tumor-Zellen. Hierzu wurden zunächst in vitro drei 
verschiedene Transfektionsreagenzien, lineares Jet-PEI, verzweigtes PEI F25-LMW und 
INTERFERin untersucht, die entweder kommerziell erhältlich oder im Labor hergestellt 
worden waren. Die Experimente konzentrierten sich auf das Kolonkarzinom als 
Tumormodell, und zwei repräsentative Zelllinien, LS174t und HCT-116, wurden für die 
Experimente ausgewählt. Als miRNAs wurden miR-143 und miR-145 eingesetzt, auf deren 
Rolle in Tumorentstehung und in Tumorprogression es au  Vorstudien bereits Hinweise 
gab.  
Es wurde in miRNA-Transfektionsexperimenten gefunden, dass miR-143 und miR-145, 
deren Level im Kolonkarzinom vermindert sind, die Tumorprogression durch verschiedene 
regulatorische Mechanismen wie Proliferation und Apoptose steuern können.  
Wichtige Gene mit funktioneller Relevanz in Tumorigenese und Tumor-Progression 
wurden durch miR-143 und miR-145 negativ reguliert. So wurde ERK5 (mitogene 
activated protein kinase), das eine wichtige Rolle in der Proliferation von Kolonkarzinom-
Zellen spielt, durch miR-143 und miR-145 supprimiert. Gleichfalls wurde eine negative 
Regulation von c-Myc durch miR-145 ermittelt, jedoch nur auf Proteinlevel und nicht auf 




abhängig waren von verschiedenen Einflüssen und Parametern wie Zelllinie, 
Transfektionsreagenz, Inkubationszeit und Konzentration des miRNA-Komplexes.  
Die zelluläre Einschleusung der microRNAs miR-143 und miR-145 zeigte folglich 
deutliche inhibierende Effekte auf die Proliferation und die Soft-Agar Kolonienbildung von 
LS174t und HCT-116-Zellen, sowie eine Apoptose-Induktion in LS174t-Zellen.  
Weiterhin wurden die Tumor-inhibierenden Effekte von miR-145 in vivo untersucht. 
Hierzu wurden athymische Nacktmäuse mit s.c. Tumor-Xenotransplantaten mit PEI-
komplexierter miR-145 durch systemische oder lokale Inj ktion behandelt. Es wurden nach 
der PEI-vermittelten miRNA-Einschleusung deutliche Antitumor-Effekte beobachtet, die 
wiederum auf der Herunterregulation von spezifischen tumorrelevanten Zielgenen 
basierten.  
Zusammenfassend kann die 'miRNA replacement therapy' somit einen viel versprechenden 
neuen Ansatz in der Tumorbehandlung darstellen, und diese Arbeit etabliert die PEI-













APS Ammonium Peroxodisulfate  
ABC Avidin-Biotin complex 
APC Adenomatous polyposis coli 
ATCC American Type Collection Center  
B-CLL B-cell chronic lymphocytic leukemia 
BMK1 Big Mitogen Kinase1 
BSA Bovine serum albumin 
Caspase cysteine aspartic acid-specific protease  
cDNA  complementary DNA 
c-Myc v-myelocytomatosis viral oncogene homolog 
DAB 3,3’-Diaminobenzidinetetrahydochloride 
DEPC Diethylpyrocarbonate 
DFF40  DNA Fragmentation Factor 40 
DFF45 DNA Fragmentation Factor 45 
DMSO Dimethylsulphoxide 
dsRNA Double strand DNA 
EDTA Ethylenediaminetetraacetic acid 
ERK1/2 Extracellular Signal Regulated Kinase1/2 
ERK5 Extracellular Signal Regulated Kinase5 
FCS Fetal calf serum 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP  Horse readish peroxidase 
IgG  Immunoglobulin G 
IHC Immunohistochemistry 
IMDM Iscove's Modified Eagle Medium 
IRS-1 Insulin-Receptor Substrate1 
kDa Kilo dalton 





mRNA messenger RNA 
NP40 Nonyl Phenoxypolyethoxylethanol 
PBS Phosphate Buffered Saline 
PBST Phosphate Buffered Saline Tween 
PCR Polymerase chain reaction 
PCNA Proliferating Cell Nuclear Antigen 
PEI   polyethylenimine 
PMSF PhenylMethylSulfonylFluoride 
pre.miRNA Precursor microRNA 
pri-miRNA Primary microRNA 
PS Phosphatidylserine 
PVDF  Polyvinylidene Fluoride 
RdRb RNA dependent RNA Polymerase 
RISC RNA interference induced silencing complex 
RNAi RNA interference  
RSK Ribosomal Synthase Kinase 
RT-PCR Reverse transcription PCR 
SDS  Sodium Dodecyl Sulphate 
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamid Gel El ctrophoresis 
SGK Serum and Glucocorticoid induced Kinase 
shRNA Short hairpin RNA 
siRNA Small interferring RNA 
TBST Tris Buffered saline tween 
TCF4 T-cell factor 4 
TEMED N, N, N', N'-Tetramethylethylenediamine 
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